<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:05:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8530730" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8530730</identifier>
        <datestamp>2021-10-25</datestamp>
        <setSpec>jcem</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Endocrinol Metab</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Endocrinol Metab</journal-id>
              <journal-id journal-id-type="publisher-id">jcem</journal-id>
              <journal-title-group>
                <journal-title>The Journal of Clinical Endocrinology and Metabolism</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0021-972X</issn>
              <issn pub-type="epub">1945-7197</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8530730</article-id>
              <article-id pub-id-type="pmcid">PMC8530730</article-id>
              <article-id pub-id-type="pmc-uid">8530730</article-id>
              <article-id pub-id-type="pmid">33705543</article-id>
              <article-id pub-id-type="pmid">33705543</article-id>
              <article-id pub-id-type="doi">10.1210/clinem/dgab160</article-id>
              <article-id pub-id-type="publisher-id">dgab160</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Online Only Articles</subject>
                  <subj-group subj-group-type="category-toc-heading">
                    <subject>Clinical Research Article</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00250</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0924-1110</contrib-id>
                  <name>
                    <surname>Goldberg</surname>
                    <given-names>Ronald B</given-names>
                  </name>
                  <xref rid="AF0001" ref-type="aff">1</xref>
                  <xref rid="c1" ref-type="corresp"/>
                  <!--dppmail@bsc.gwu.edu-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tripputi</surname>
                    <given-names>Mark T</given-names>
                  </name>
                  <xref rid="AF0002" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boyko</surname>
                    <given-names>Edward J</given-names>
                  </name>
                  <xref rid="AF0003" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Budoff</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref rid="AF0004" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Zsu-Zsu</given-names>
                  </name>
                  <xref rid="AF0005" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clark</surname>
                    <given-names>Jeanne M</given-names>
                  </name>
                  <xref rid="AF0006" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dabelea</surname>
                    <given-names>Dana M</given-names>
                  </name>
                  <xref rid="AF0007" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8457-4404</contrib-id>
                  <name>
                    <surname>Edelstein</surname>
                    <given-names>Sharon L</given-names>
                  </name>
                  <xref rid="AF0002" ref-type="aff">2</xref>
                  <xref rid="c2" ref-type="corresp"/>
                  <!--sharone@bsc.gwu.edu-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gerszten</surname>
                    <given-names>Robert E</given-names>
                  </name>
                  <xref rid="AF0008" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Horton</surname>
                    <given-names>Edward</given-names>
                  </name>
                  <xref rid="AF0009" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mather</surname>
                    <given-names>Kieren J</given-names>
                  </name>
                  <xref rid="AF0010" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perreault</surname>
                    <given-names>Leigh</given-names>
                  </name>
                  <xref rid="AF0011" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Temprosa</surname>
                    <given-names>Marinella</given-names>
                  </name>
                  <xref rid="AF0002" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wallia</surname>
                    <given-names>Amisha</given-names>
                  </name>
                  <xref rid="AF0012" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Watson</surname>
                    <given-names>Karol</given-names>
                  </name>
                  <xref rid="AF0013" ref-type="aff">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Irfan</surname>
                    <given-names>Zeb</given-names>
                  </name>
                  <xref rid="AF0014" ref-type="aff">14</xref>
                </contrib>
              </contrib-group>
              <aff id="AF0001"><label>1</label><institution>Diabetes Research Institute, Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine</institution>, <addr-line>Miami, FL 33136</addr-line><country country="US">USA</country></aff>
              <aff id="AF0002"><label>2</label><institution>Milken Institute School of Public Health and Health Services, The Biostatistics Center, George Washington University</institution>, <addr-line>Rockville, MD 20852</addr-line><country country="US">USA</country></aff>
              <aff id="AF0003"><label>3</label><institution>University of Washington, Department of Medicine</institution>, <addr-line>Seattle, WA 98108</addr-line><country country="US">USA</country></aff>
              <aff id="AF0004"><label>4</label><institution>Los Angeles Biomedical Research Institute</institution>, <addr-line>Torrance CA 90502</addr-line><country country="US">USA</country></aff>
              <aff id="AF0005"><label>5</label><institution>Division of Endocrinology, Bone, and Metabolism, Beth Israel Deaconess Medical Center</institution>, <addr-line>Harvard, Boston, MA 02215</addr-line>, <country country="US">USA</country></aff>
              <aff id="AF0006"><label>6</label><institution>Division of General Internal Medicine, The Johns Hopkins University</institution>, <addr-line>Baltimore MD 21287</addr-line><country country="US">USA</country></aff>
              <aff id="AF0007"><label>7</label><institution>Colorado School of Public Health, University of Colorado Anschutz Medical Campus</institution>, <addr-line>Aurora, CO 80045</addr-line><country country="US">USA</country></aff>
              <aff id="AF0008"><label>8</label><institution>Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center</institution>, <addr-line>Harvard, Boston, MA 02215</addr-line>, <country country="US">USA</country></aff>
              <aff id="AF0009"><label>9</label><institution>Joslin Diabetes Center</institution>, <addr-line>Boston, MA 02215</addr-line><country country="US">USA</country></aff>
              <aff id="AF0010"><label>10</label><institution>Indiana University of Medicine</institution>, <addr-line>Indianapolis IN 46202</addr-line><country country="US">USA</country></aff>
              <aff id="AF0011"><label>11</label><institution>University of Colorado Anschutz Medical Campus</institution>, <addr-line>Aurora, CO 80045</addr-line><country country="US">USA</country></aff>
              <aff id="AF0012"><label>12</label><institution>Northwestern University Feinberg School of Medicine</institution>, <addr-line>Chicago IL 60610</addr-line><country country="US">USA</country></aff>
              <aff id="AF0013"><label>13</label><institution>David Geffen School of Medicine at UCLA</institution>, <addr-line>Los Angeles, CA 90095</addr-line><country country="US">USA</country></aff>
              <aff id="AF0014"><label>14</label><institution>J. W. Ruby Memorial Hospital</institution>, <addr-line>Morgantown, WV 26505</addr-line><country country="US">USA</country></aff>
              <author-notes>
                <corresp id="c1"><bold><italic toggle="yes">Correspondence:</italic></bold> Ronald B Goldberg, MD, Diabetes Research Institute, Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, 1450 Northwest 10th Avenue, Miami, FL 33136 USA. Email: <email>dppmail@bsc.gwu.edu</email></corresp>
                <corresp id="c2">Sharon L. Edelstein, ScM, The Biostatistics Center, Milken Institute School of Public Health, The George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852, USA. Email: <email>sharone@bsc.gwu.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-03-11">
                <day>11</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>11</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <volume>106</volume>
              <issue>11</issue>
              <fpage>e4746</fpage>
              <lpage>e4765</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
                <date date-type="editorial-decision">
                  <day>08</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>07</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="dgab160.pdf"/>
              <related-article related-article-type="companion" ext-link-type="doi" id="u1" xlink:href="10.1210/clinem/dgab332"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s0101">
                  <title>Context</title>
                  <p>There is little information about fatty liver in prediabetes as it transitions to early diabetes.</p>
                </sec>
                <sec id="s0102">
                  <title>Objective</title>
                  <p>This study is aimed at evaluating the prevalence and determinants of fatty liver in the Diabetes Prevention Program (DPP).</p>
                </sec>
                <sec id="s0103">
                  <title>Methods</title>
                  <p>We measured liver fat as liver attenuation (LA) in Hounsfield units (HU) in 1876 participants at ~14 years following randomization into the DPP, which tested the effects of lifestyle or metformin interventions versus standard care to prevent diabetes. LA was compared among intervention groups and in those with versus without diabetes, and associations with baseline and follow-up measurements of anthropometric and metabolic covariates were assessed.</p>
                </sec>
                <sec id="s0104">
                  <title>Results</title>
                  <p>There were no differences in liver fat between treatment groups at 14 years of follow-up. Participants with diabetes had lower LA (mean ± SD: 46 ± 16 vs 51 ± 14 HU; <italic toggle="yes">P</italic> &lt; 0.001) and a greater prevalence of fatty liver (LA &lt; 40 HU) (34% vs 17%; <italic toggle="yes">P</italic> &lt; 0.001). Severity of metabolic abnormalities at the time of LA evaluation was associated with lower LA categories in a graded manner and more strongly in those with diabetes. Averaged annual fasting insulin (an index of insulin resistance [OR, 95% CI 1.76, 1.41-2.20]) waist circumference (1.63, 1.17-2.26), and triglyceride (1.42, 1.13-1.78), but not glucose, were independently associated with LA &lt; 40 HU prevalence.</p>
                </sec>
                <sec id="s0105">
                  <title>Conclusion</title>
                  <p>Fatty liver is common in the early phases of diabetes development. The association of LA with insulin resistance, waist circumference, and triglyceride levels emphasizes the importance of these markers for hepatic steatosis in this population and that assessment of hepatic fat in early diabetes development is warranted.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Lipid metabolism</kwd>
                <kwd>weight regulation and obesity</kwd>
                <kwd>prediction and prevention of type 2 diabetes</kwd>
                <kwd>imaging</kwd>
                <kwd>hepatic fat</kwd>
                <kwd>diabetes development</kwd>
                <kwd>lifestyle</kwd>
                <kwd>metformin</kwd>
              </kwd-group>
              <counts>
                <page-count count="20"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>Fatty liver is common in type 2 diabetes and is associated with increased morbidity and mortality (<xref rid="CIT0001" ref-type="bibr">1</xref>). The accumulation of liver fat in diabetes is thought to result from increased hepatic fatty acid availability and deposition as triglyceride contributing to the development of hepatic insulin resistance and increased hepatic glucose and triglyceride output (<xref rid="CIT0002" ref-type="bibr">2</xref>). These metabolic abnormalities are part of the pathophysiology leading to diabetes, and fatty liver is known to both predate (<xref rid="CIT0003" ref-type="bibr">3</xref>) and predict (<xref rid="CIT0004" ref-type="bibr">4</xref>) the development of diabetes. Since prediabetes is the precursor to diabetes, such individuals should be susceptible to fatty liver. However, there is little information about the prevalence of fatty liver in categorically defined prediabetes and early diabetes. It is known that prediabetes is a common finding in subjects with nonalcoholic fatty liver disease (NAFLD) and the prevalence of fatty liver increases in relation to the glycated hemoglobin A1c (HbA1c) level in nondiabetic subjects (<xref rid="CIT0003" ref-type="bibr">3</xref>), suggesting that dysglycemia is a risk factor for fatty liver. Nevertheless, there have been no systematic studies of liver fat and its determinants in populations with defined prediabetes nor what the impact of diabetes development is on liver fat in these individuals.</p>
            <p>The Diabetes Prevention Program Outcome Study (DPPOS) is the long-term follow-up study of the Diabetes Prevention Program (DPP) a placebo-controlled randomized clinical trial that demonstrated in overweight subjects with impaired glucose tolerance (IGT) that intensive lifestyle or metformin interventions reduced diabetes development compared to placebo plus standard care over a 2.8-year period by 58% and 31%, respectively (<xref rid="CIT0005" ref-type="bibr">5</xref>). These interventions also had differing effects on body weight, insulin sensitivity, and circulating lipids (<xref rid="CIT0005" ref-type="bibr">5</xref>). Treatment group differences in diabetes incidence persisted following this initial intervention period, with 27% and 18% reductions in diabetes incidence for lifestyle and metformin, respectively, at year 11 of DPPOS, approximately 15 years after randomization (<xref rid="CIT0006" ref-type="bibr">6</xref>). DPPOS is evaluating the long-term effects of these interventions on diabetes development and its complications. To this end, computed tomographic (CT) studies were performed at year 10 of DPPOS, approximately 14 years after randomization for coronary calcium scoring (CAC) (<xref rid="CIT0007" ref-type="bibr">7</xref>) and included axial slices through the liver, providing an opportunity to assess the characteristics, metabolic features, and determinants of liver fat in those who developed diabetes versus those who did not in a secondary analysis.</p>
            <sec sec-type="materials" id="s1">
              <title>Methods</title>
              <sec id="s2">
                <title>DPP and DPPOS Design, Randomization, and Masking</title>
                <p>Selection criteria for the DPP (ClinicalTrials.gov registration no. NCT00004992) included: age ≥ 25 years, body mass index (BMI) ≥ 24 kg/m<sup>2</sup> (≥22 kg/m<sup>2</sup> in Asian Americans), fasting plasma glucose (FG) levels between 5.3 and 6.9 mmol/L (&lt;6.9 mmol/L in American Indians), and IGT (2-hour post-load glucose of 7.8-11.0 mmol/L). Written informed consent was obtained from all participants before screening, consistent with the Declaration of Helsinki and the guidelines of each center’s institutional review board. In total, 3234 participants were originally randomly assigned to 1 of 3 interventions: metformin 850 mg or placebo twice daily with double blinding, or an intensive program of lifestyle modification. The goals of intensive lifestyle change were to achieve and maintain weight reduction of at least 7% through consumption of a low-calorie, low-fat diet and to engage in at least 150 minutes/week of physical activity. The placebo group was managed according to standard healthcare recommendations only. Diabetes was diagnosed on the basis of an annual oral glucose tolerance test or a semiannual fasting plasma glucose test according to American Diabetes Association criteria (<xref rid="CIT0008" ref-type="bibr">8</xref>) and required confirmation by a second test, usually within 6 weeks. Once diabetes was diagnosed or an HbA1c of ≥53mmol/mol was reached in the metformin group, study drug was discontinued and diabetes management, including treatment with metformin or other medicines was transferred to the participant’s health care provider. At DPP-end, placebo and metformin groups were unmasked to their treatment assignment, and all participants were offered intensive lifestyle intervention in a group format during a 1-year bridge period. All surviving consented DPP participants (n = 3149), regardless of diabetes status, were invited to participate in the DPPOS and 2776 (88%) joined (<xref rid="CIT0006" ref-type="bibr">6</xref>). In addition to maintenance group lifestyle sessions offered to all participants, the original lifestyle group was offered supplementary group programs reinforcing behavioral self-management activities twice per year. During DPPOS, metformin, now unmasked, continued to be provided to participants randomized to metformin who remained eligible.</p>
              </sec>
              <sec id="s3">
                <title>Clinical and Metabolic Variables</title>
                <p>Standardized questionnaires were used to obtain demographic and clinical data. BP, height, and weight were measured using standardized techniques. HbA1c, FG, fasting insulin (FI, as a measure of insulin resistance), lipid profile, high-sensitivity C-reactive protein (CRP), adiponectin, and plasma tissue plasminogen activator (tPA) (as a surrogate for plasminogen activator inhibitor 1 [PAI-1] measurements) were performed at the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle) as previously reported (<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>). These assessments were performed at baseline and annually thereafter except for CRP, adiponectin, and tPA, which were measured at baseline and DPP year 1; tPA and CRP were also measured at DPPOS year 1 and CRP additionally at DPPOS year 5. Dimethylguanidinovaleric acid (DMGV), a recently identified metabolite biomarker of CT-defined NAFLD, was measured at baseline only, by liquid chromatography-accurate-mass tandem mass spectrometry (<xref rid="CIT0011" ref-type="bibr">11</xref>) in 1276 participants and values were normalized by transformation to have a mean of 0 and an SD of 1. CAC scoring, prevalence of dyslipidemia (annually) and microangiopathy (at year 11) were assessed by previously reported methods (<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>).</p>
                <sec id="s4">
                  <title>Hepatic fat measurements</title>
                  <list list-type="simple">
                    <list-item>
                      <p>(i) Image acquisition</p>
                    </list-item>
                  </list>
                  <p>Each eligible participant underwent 2 consecutive nonenhanced cardiac CT scans during a single session. We studied 1876 of the original 2776 DPPOS participants (68%), comprising active DPPOS participants with no condition excluding them from CT scanning, not drinking &gt;7 alcoholic drinks/week in women or &gt;14 drinks/week in men nor having known hepatitis other than NAFLD, not taking steroids or amiodarone, and who volunteered for the study. Participants were scanned by multi–detector row CT scanners by certified technologists at each clinical site using electrocardiogram-triggered scan acquisition at 50% of the R-R interval using a 2.5-mm slice thickness from the carina to below the apex of the heart and containing images of the liver and spleen. The images were transferred to the central reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California). Two experienced readers independently read all CT scans in a manner blinded to patient characteristics and treatment assignment.</p>
                  <list list-type="simple">
                    <list-item>
                      <p>(ii) Liver fat measurements</p>
                    </list-item>
                  </list>
                  <p>Both scans for each participant were examined and the one with the largest liver scan span was selected for measurement of liver fat (<xref rid="CIT0012" ref-type="bibr">12</xref>). Liver attenuation (LA) was measured as Hounsfield unit (HU) values using regions of interest (ROI) &gt; 100 mm<sup>2</sup> in area. Two ROIs were placed in the right liver lobe anteroposteriorly. ROIs with larger areas were used whenever possible to include a greater area of the liver while taking care to exclude regions of nonuniform parenchymal attenuation, including hepatic vessels. Seventy individuals had inadequate visualization of the liver, leaving a final total of 1876 participants for analysis of hepatic fat. Since 189 scans did not contain images of the spleen, hepatic fat was expressed as liver attenuation only rather than liver/spleen attenuation ratio. Compared with the 900 participants who did not have a scan, at the DPP baseline examination these 1876 participants had slightly higher minority race/ethnicity representation (48% vs 40% non-white), were younger (50.2 vs 52.9 years), had similar BMI (33.7 vs 34.0 kg/m<sup>2</sup>), and lower systolic blood pressure (BP) (122.7 vs 125.6 mm Hg), but the proportion having hepatic fat measurements did not differ between treatment groups. Data were assumed to be missing at random. <xref rid="F1" ref-type="fig">Figure 1</xref> shows the CONSORT [Consolidated Standards of Reporting Trials] flow diagram.</p>
                  <fig position="float" id="F1">
                    <label>Figure 1.</label>
                    <caption>
                      <p>CONSORT flow diagram.</p>
                    </caption>
                    <graphic xlink:href="dgab160f0001" position="float"/>
                  </fig>
                </sec>
              </sec>
              <sec id="s5">
                <title>Statistical Methods</title>
                <p>The 2 primary liver fat outcome measures were mean LA and LA &lt; 40 prevalence. Hepatic fat was analyzed as a continuous variable (LA in HU), where lower LA indicates a greater amount of hepatic fat (<xref rid="CIT0013" ref-type="bibr">13</xref>) and in categories of LA (2-category outcome: LA &lt; 40, ≥40, and 3-category outcome: LA &lt; 40, 40–50, &gt;50), where LA &lt; 40 is taken to indicate a fatty liver (≥30% fat) (<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>). Although liver fat prevalence categories are typically presented using the 2-category outcome, namely LA &lt; 40 and ≥40, we also explored whether a 3-category outcome was of value in this population (<xref rid="CIT0013" ref-type="bibr">13</xref>).</p>
                <p>Differences among subgroups were assessed using ANOVA and Kruskal-Wallis nonparametric tests for continuous and chi-square tests for categorical measures. Trend tests across the 3-category LA outcome for continuous covariates were assessed with a rank-based test of monotonicity (ie, test of Spearman correlation = 0), and for binomial covariates the 2-sided Cochran-Armitage test of proportions was used. Model-based association of covariates with outcomes were assessed using linear, logistic, and/or multinomial models, according to the nature of the outcome. The only exception was for CAC measured as log(CAC+1), where <italic toggle="yes">P</italic> values were calculated from a tobit model because of the large number of participants with a CAC measurement of zero (<xref rid="CIT0007" ref-type="bibr">7</xref>). Separate models tested for effects of baseline covariates and for baseline-adjusted mean annual follow-up measures of covariates. All models were developed without diabetes status in the model except where stated. Measures of association were expressed as differences in mean LA in linear models, odds ratios for LA &lt; 40 in logistic models, and odds ratios for LA &lt; 40 and LA 40 to 50 in the multinomial models using LA &gt; 50 as the referent. Increased hepatic fat is indicated by negative changes in mean LA and odds ratios &gt; 1 for LA categories.</p>
              </sec>
            </sec>
            <sec id="s6">
              <title>Results</title>
              <sec id="s7">
                <title>Characteristics of the Cohort</title>
                <p><xref rid="T1" ref-type="table">Table 1</xref> shows the characteristics of the cohort of 1876 participants in this study at DPP baseline and at the time of the scan in year 10 of DPPOS (average 13.7 years after randomization) by intervention group. There were significant differences from placebo in the metformin group for FG, in the lifestyle group for triglyceride, adiponectin, and diabetes incidence, and for tPA values and diabetes duration in both active intervention groups. Diabetes had developed in 52% (n = 319) of the lifestyle, 54% (n = 333) of the metformin, and 60% (n = 382) of the placebo groups (total n = 1034) at the time of the scan. Despite these group differences, there were no differences in mean LA or prevalence of LA &lt; 40 by intervention groups. Therefore, the data from the treatment groups were pooled in all analyses and stratified by diabetes status. Treatment effects did not differ in demographic subgroups but there was a significant diabetes × treatment group interaction (<italic toggle="yes">P</italic> &lt; 0.01) for both mean LA and LA &lt; 40. Pairwise comparisons demonstrated that within the nondiabetes subgroup, percent LA &lt; 40 was nominally greater and mean LA was lower with metformin versus placebo and lifestyle treatments. The opposite was true in the diabetes subgroup, where percent LA &lt; 40 was less and mean LA greater with metformin treatment versus the other 2 groups. The only pairwise comparisons that reached significance (<italic toggle="yes">P</italic> &lt; 0.05) were for LA &lt; 40 within the nondiabetes group for metformin versus placebo.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1.</label>
                  <caption>
                    <p>Characteristics (mean ± SEM or mean [95%CI]) of the cohort at DPP baseline and at the time of the scan (except where noted)</p>
                  </caption>
                  <table frame="vsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th rowspan="1" colspan="1">DPP baseline (mean ± SEM)</th>
                        <th colspan="3" rowspan="1">Mean [95% CI] during scan year</th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th rowspan="1" colspan="1">All</th>
                        <th rowspan="1" colspan="1">Lifestyle</th>
                        <th rowspan="1" colspan="1">Metformin</th>
                        <th rowspan="1" colspan="1">Placebo</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">N</td>
                        <td rowspan="1" colspan="1">1876</td>
                        <td rowspan="1" colspan="1">615</td>
                        <td rowspan="1" colspan="1">620</td>
                        <td rowspan="1" colspan="1">641</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Age at baseline and scan (y)</td>
                        <td rowspan="1" colspan="1">50.2 ± 0.2</td>
                        <td rowspan="1" colspan="1">64.1 [63.4, 64.9]</td>
                        <td rowspan="1" colspan="1">64.1 [63.3, 64.9]</td>
                        <td rowspan="1" colspan="1">63.4 [62.7, 64.2]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">972 (51.8%)</td>
                        <td rowspan="1" colspan="1">309 (50.2%)</td>
                        <td rowspan="1" colspan="1">334 (53.9%)</td>
                        <td rowspan="1" colspan="1">329 (51.3%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black</td>
                        <td rowspan="1" colspan="1">399 (21.3%)</td>
                        <td rowspan="1" colspan="1">131 (21.3%)</td>
                        <td rowspan="1" colspan="1">134 (21.6%)</td>
                        <td rowspan="1" colspan="1">134 (20.9%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Hispanic</td>
                        <td rowspan="1" colspan="1">309 (16.5%)</td>
                        <td rowspan="1" colspan="1">100 (16.3%)</td>
                        <td rowspan="1" colspan="1">101 (16.3%)</td>
                        <td rowspan="1" colspan="1">108 (16.8%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">87 (4.6%)</td>
                        <td rowspan="1" colspan="1">37 (6.0%)</td>
                        <td rowspan="1" colspan="1">20 (3.2%)</td>
                        <td rowspan="1" colspan="1">30 (4.7%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> American Indian</td>
                        <td rowspan="1" colspan="1">109 (5.8%)</td>
                        <td rowspan="1" colspan="1">38 (6.2%)</td>
                        <td rowspan="1" colspan="1">31 (5.0%)</td>
                        <td rowspan="1" colspan="1">40 (6.2%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Sex</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Female</td>
                        <td rowspan="1" colspan="1">1303 (69.5%)</td>
                        <td rowspan="1" colspan="1">426 (69.3%)</td>
                        <td rowspan="1" colspan="1">426 (68.7%)</td>
                        <td rowspan="1" colspan="1">451 (70.4%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Male</td>
                        <td rowspan="1" colspan="1">573 (30.5%)</td>
                        <td rowspan="1" colspan="1">189 (30.7%)</td>
                        <td rowspan="1" colspan="1">194 (31.3%)</td>
                        <td rowspan="1" colspan="1">190 (29.6%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                        <td rowspan="1" colspan="1">33.7 ± 0.1</td>
                        <td rowspan="1" colspan="1">32.6 [32, 33.1]</td>
                        <td rowspan="1" colspan="1">32.7 [32.2, 33.2]</td>
                        <td rowspan="1" colspan="1">33.4 [32.8, 33.9]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Waist circumference (cm)</td>
                        <td rowspan="1" colspan="1">104.4 ± 0.3</td>
                        <td rowspan="1" colspan="1">105.8 [104.7, 107]</td>
                        <td rowspan="1" colspan="1">106.0 [104.9, 107.2]</td>
                        <td rowspan="1" colspan="1">107.3 [106.2, 108.4]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Fasting glucose (mmol/L)</td>
                        <td rowspan="1" colspan="1">5.9 ± 0.0</td>
                        <td rowspan="1" colspan="1">6.7 [6.5, 6.8]</td>
                        <td rowspan="1" colspan="1">6.5 [6.3, 6.6] <sup>b</sup></td>
                        <td rowspan="1" colspan="1">6.9 [6.7, 7.0]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">2-hour glucose (mmol/L)</td>
                        <td rowspan="1" colspan="1">9.1 ± 0.0</td>
                        <td rowspan="1" colspan="1">8.3 [8.0, 8.5]</td>
                        <td rowspan="1" colspan="1">8.2 [8.0, 8.5]</td>
                        <td rowspan="1" colspan="1">8.2 [7.9, 8.5]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HbA1c (mmol/mol)</td>
                        <td rowspan="1" colspan="1">41.3 ± 0.1</td>
                        <td rowspan="1" colspan="1">43.7 [42.7, 44.8]</td>
                        <td rowspan="1" colspan="1">43.1 [42.1, 44.1]</td>
                        <td rowspan="1" colspan="1">44.4 [43.4, 45.5]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Fasting insulin (pmol/L)</td>
                        <td rowspan="1" colspan="1">185.1 ± 2.4</td>
                        <td rowspan="1" colspan="1">238.2 [219.7, 256.6]</td>
                        <td rowspan="1" colspan="1">254.5 [236.2, 272.7]</td>
                        <td rowspan="1" colspan="1">262.8 [244.8, 280.8]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Incident diabetes</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">319 (52%)<sup>b</sup></td>
                        <td rowspan="1" colspan="1">333 (54%)</td>
                        <td rowspan="1" colspan="1">382 (60%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diabetes duration (y)</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">7.4 [7.0, 7.8] <sup>b,c</sup></td>
                        <td rowspan="1" colspan="1">8.5 [8.1, 8.9] <sup>b</sup></td>
                        <td rowspan="1" colspan="1">9.1 [8.7, 9.5]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Metabolic syndrome</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">263 (43%)</td>
                        <td rowspan="1" colspan="1">266 (43%)</td>
                        <td rowspan="1" colspan="1">316 (49%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Systolic BP (mm/Hg)</td>
                        <td rowspan="1" colspan="1">122.7 ± 0.3</td>
                        <td rowspan="1" colspan="1">121.0 [119.8, 122.2]</td>
                        <td rowspan="1" colspan="1">121.4 [120.2, 122.6]</td>
                        <td rowspan="1" colspan="1">121.0 [119.8, 122.1]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diastolic BP (mm/Hg)</td>
                        <td rowspan="1" colspan="1">78.1 ± 0.2</td>
                        <td rowspan="1" colspan="1">71.0 [70.2, 71.7]</td>
                        <td rowspan="1" colspan="1">71.3 [70.6, 72.1]</td>
                        <td rowspan="1" colspan="1">71.0 [70.2, 71.7]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Antihypertensive use</td>
                        <td rowspan="1" colspan="1">15%</td>
                        <td rowspan="1" colspan="1">346 (58%)</td>
                        <td rowspan="1" colspan="1">387 (64%)</td>
                        <td rowspan="1" colspan="1">392 (63%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Triglyceride (mmol/L)</td>
                        <td rowspan="1" colspan="1">1.8 ± 0.0</td>
                        <td rowspan="1" colspan="1">1.4 [1.4, 1.5] <sup>b</sup></td>
                        <td rowspan="1" colspan="1">1.5 [1.4, 1.6]</td>
                        <td rowspan="1" colspan="1">1.6 [1.5, 1.6]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HDL-C (mmol/L)</td>
                        <td rowspan="1" colspan="1">1.2 ± 0.0<sup>a</sup></td>
                        <td rowspan="1" colspan="1">1.4 [1.4, 1.4]</td>
                        <td rowspan="1" colspan="1">1.4 [1.4, 1.4]</td>
                        <td rowspan="1" colspan="1">1.3 [1.3, 1.4]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">LDL-C (mmol/L)</td>
                        <td rowspan="1" colspan="1">3.2 ± 0.0</td>
                        <td rowspan="1" colspan="1">2.6 [2.6, 2.7]</td>
                        <td rowspan="1" colspan="1">2.6 [2.5, 2.6]</td>
                        <td rowspan="1" colspan="1">2.6 [2.5, 2.6]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Statin use</td>
                        <td rowspan="1" colspan="1">4%</td>
                        <td rowspan="1" colspan="1">329 (55%)</td>
                        <td rowspan="1" colspan="1">357 (59%)</td>
                        <td rowspan="1" colspan="1">373 (59%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CRP (nmol/L)</td>
                        <td rowspan="1" colspan="1">0.6 ± 0.0</td>
                        <td rowspan="1" colspan="1">0.5 [0.4, 0.5]</td>
                        <td rowspan="1" colspan="1">0.4 [0.4, 0.5]</td>
                        <td rowspan="1" colspan="1">0.5 [0.4, 0.5]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Adiponectin (ug/mL) </td>
                        <td rowspan="1" colspan="1">7.9 ± 0.1</td>
                        <td rowspan="1" colspan="1">8.8 [8.5, 9.1] <sup>b,c</sup></td>
                        <td rowspan="1" colspan="1">8.2 [7.9, 8.5]</td>
                        <td rowspan="1" colspan="1">7.9 [7.6, 8.2]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">tPA (ng/mL) </td>
                        <td rowspan="1" colspan="1">10.0 ± 0.1<sup>a</sup></td>
                        <td rowspan="1" colspan="1">9.0 [8.7, 9.3] <sup>b,c</sup></td>
                        <td rowspan="1" colspan="1">8.0 [7.7, 8.3] <sup>b</sup></td>
                        <td rowspan="1" colspan="1">9.6 [9.3, 9.9]</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline ALT (U/L)</td>
                        <td rowspan="1" colspan="1">20.3 ± 0.3 </td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline AST (U/L)</td>
                        <td rowspan="1" colspan="1">20.5 ± 0.2</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">LA &lt; 40 HU</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">143 (23%)</td>
                        <td rowspan="1" colspan="1">154 (25%)</td>
                        <td rowspan="1" colspan="1">163 (25%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Liver attenuation (HU)</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">48.6 [47.4, 49.8]</td>
                        <td rowspan="1" colspan="1">48.6 [47.4, 49.8]</td>
                        <td rowspan="1" colspan="1">47.6 [46.4, 48.8]</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="fn-0100">
                      <p>Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; CRP, high-sensitivity C-reactive protein; DPP, Diabetes Prevention Program; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HU, Hounsfield units; LA, liver attenuation; LDL-C, low-density lipoprotein cholesterol; tPA, tissue plasminogen activator.</p>
                    </fn>
                    <fn id="fn-0101">
                      <p><sup>a</sup><italic toggle="yes">P</italic> &lt; 0.05 for baseline-treatment group comparison.</p>
                    </fn>
                    <fn id="fn-0102">
                      <p><sup>b</sup><italic toggle="yes">P</italic> &lt; 0.05 for difference from placebo for lifestyle and/or metformin groups at follow-up.</p>
                    </fn>
                    <fn id="fn-0103">
                      <p><sup>c</sup><italic toggle="yes">P</italic> &lt; 0.05 for comparison of follow-up lifestyle and metformin groups.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s8">
                <title>Distribution of Mean LA and LA &lt; 40 by Demographic Factors and Nondiabetes/Diabetes Status</title>
                <p><xref rid="F2" ref-type="fig">Figures 2A</xref> and <xref rid="F2" ref-type="fig">2B</xref> present mean LA and prevalence of LA &lt; 40 for the entire cohort by intervention groups, demographic factors, and diabetes status. Overall mean LA was 48.2 HU and LA &lt; 40 prevalence was 25%. Those with diabetes at the time of scanning had lower mean LA values than those without diabetes (46 ± 16 vs 51 ± 14 HU; <italic toggle="yes">P</italic> &lt; 0.001), and the prevalence of LA &lt; 40 was about twice that in those without diabetes overall (31% vs 17%; <italic toggle="yes">P</italic> &lt; 0.001) and in all race/ethnic groups except for African Americans, where there was no difference between those with versus without diabetes. Mean LA was higher in African Americans than non-Hispanic Whites and Hispanics (54.7 vs 47.4 HU; <italic toggle="yes">P</italic> &lt; 0.001 for both) and LA &lt; 40 prevalence lower (9.8% vs 25.8%; <italic toggle="yes">P</italic> &lt; 0.001 for both), whereas the opposite was true for American Indians vs non-Hispanic Whites overall (mean LA: 40.3 vs 47.4 HU and LA &lt; 40: 44.0% vs 25.8%; <italic toggle="yes">P</italic> &lt; 0.001 for both) as well as in those with or without diabetes. There was also an inverse age trend toward lower mean LA (44.6, 48.2, 53.5 HU in those &lt;60, 60 to 69, and &gt;70 years of age; <italic toggle="yes">P</italic> &lt; 0.001) and greater LA &lt; 40 prevalence (33.7%, 24.7%, 11.5%; <italic toggle="yes">P</italic> &lt; 0.001). There was no heterogeneity in these associations by diabetes status. Sex was not associated with liver fat (mean LA: 47.9 HU in males vs 48.4 HU in females) nor the proportion with LA &lt; 40 (23% in males vs 25% in females).</p>
                <fig position="float" id="F2">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Mean (black dot) LA in HU and 95% CI (shaded bar) (Panel A) and prevalence of LA &lt; 40 HU and 95% CI (Panel B) by intervention groups, demographic factors, and diabetes status.</p>
                  </caption>
                  <graphic xlink:href="dgab160f0002" position="float"/>
                </fig>
                <p><xref rid="F3" ref-type="fig">Figure 3</xref> presents the LA frequency distribution in the groups with and without diabetes. Although there is considerable overlap, the distribution of LA values in the group with diabetes was different from those without diabetes (<italic toggle="yes">P</italic> &lt; 0.001) and is shifted toward lower attenuation, with medians of 48.6 and 54.1 HU in the groups with and without diabetes respectively.</p>
                <fig position="float" id="F3">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Empirical probability density functions of LA in the groups with and without diabetes. The total area under each curve is 1, and the proportion of participants with LA measurements between any 2 chosen values is the area under the curve between those points.</p>
                  </caption>
                  <graphic xlink:href="dgab160f0003" position="float"/>
                </fig>
              </sec>
              <sec id="s9">
                <title>Cross-Sectional Associations of Metabolic and Clinical Factors With LA Categories</title>
                <p>We next evaluated whether LA expressed as a 3-category outcome was related to standard metabolic and clinical abnormalities at the time of the scan and how these relationships differed by diabetes status (<xref rid="T2" ref-type="table">Table 2</xref>). The prevalence of LA &lt; 40 HU in those with diabetes compared to those without was higher (30.5% vs 17.3%) and of LA &gt; 50 was lower (47% vs 62.1%). Comparing those with and without diabetes, all metabolic and clinical variables were higher in the group with diabetes except high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) values, which were lower. There were graded differences in glycemic measures, FI, anthropometric measures, triglyceride, and HDL-C values and also prevalence of metabolic syndrome by LA categories within each of the 2 subgroups, with significant interactions for glycemia measures, FI, and LDL-C between diabetes status subgroups and LA categories. Among participants with diabetes, mean LA trended higher with increased diabetes duration and there was a significant though weak positive correlation between diabetes duration and mean LA (<italic toggle="yes">r</italic><sup><italic toggle="yes">2</italic></sup> = 1%; <italic toggle="yes">P</italic> &lt; 0.01). This was not accounted for by age or influenced by treatment group in separate analyses (data not shown). There were no differences in prevalence of hypertension, microangiopathy, or CAC scores by LA categories.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Metabolic factors and clinical measures (median [IQR] or N [%]) during the year of the scan</p>
                  </caption>
                  <table frame="vsides" rules="groups">
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th colspan="4" rowspan="1">No Diabetes</th>
                        <th colspan="4" rowspan="1">Diabetes</th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th rowspan="1" colspan="1">LA &lt; 40</th>
                        <th rowspan="1" colspan="1">LA 40–50</th>
                        <th rowspan="1" colspan="1">LA &gt; 50</th>
                        <th rowspan="1" colspan="1">
                          <italic toggle="yes">P</italic>
                          <sup>a</sup>
                        </th>
                        <th rowspan="1" colspan="1">LA &lt; 40</th>
                        <th rowspan="1" colspan="1">LA 40–50</th>
                        <th rowspan="1" colspan="1">LA &gt; 50</th>
                        <th rowspan="1" colspan="1">
                          <italic toggle="yes">P</italic>
                          <sup>a</sup>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">N</td>
                        <td rowspan="1" colspan="1">142</td>
                        <td rowspan="1" colspan="1">173</td>
                        <td rowspan="1" colspan="1">527</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">318</td>
                        <td rowspan="1" colspan="1">235</td>
                        <td rowspan="1" colspan="1">481</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">LA category prevalence<sup>b</sup></td>
                        <td rowspan="1" colspan="1">17.3%</td>
                        <td rowspan="1" colspan="1">20.6%</td>
                        <td rowspan="1" colspan="1">62.1%</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1">30.5%</td>
                        <td rowspan="1" colspan="1">22.5%</td>
                        <td rowspan="1" colspan="1">47%</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Female</td>
                        <td rowspan="1" colspan="1">105 (74%)</td>
                        <td rowspan="1" colspan="1">112 (65%)</td>
                        <td rowspan="1" colspan="1">367 (70%)</td>
                        <td rowspan="1" colspan="1">0.206</td>
                        <td rowspan="1" colspan="1">223 (70%)</td>
                        <td rowspan="1" colspan="1">157 (67%)</td>
                        <td rowspan="1" colspan="1">339 (71%)</td>
                        <td rowspan="1" colspan="1">0.583</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Caucasian<sup>c</sup></td>
                        <td rowspan="1" colspan="1">79 (56%)</td>
                        <td rowspan="1" colspan="1">102 (59%)</td>
                        <td rowspan="1" colspan="1">290 (55%)</td>
                        <td rowspan="1" colspan="1">0.663</td>
                        <td rowspan="1" colspan="1">172 (54%)</td>
                        <td rowspan="1" colspan="1">117 (50%)</td>
                        <td rowspan="1" colspan="1">212 (44%)</td>
                        <td rowspan="1" colspan="1">0.019</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>METABOLIC</bold>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Fasting glucose (mmol/L)<sup>c,d</sup></td>
                        <td rowspan="1" colspan="1">5.8 [5.4, 6.2]</td>
                        <td rowspan="1" colspan="1">5.8 [5.5, 6.0]</td>
                        <td rowspan="1" colspan="1">5.7 [5.3, 6.0]</td>
                        <td rowspan="1" colspan="1">0.003<sup>e</sup></td>
                        <td rowspan="1" colspan="1">7.3 [6.3, 8.6]</td>
                        <td rowspan="1" colspan="1">7.0 [6.1, 8.1]</td>
                        <td rowspan="1" colspan="1">6.5 [5.8, 7.5]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">2-hour glucose (mmol/L)<sup>c,d</sup></td>
                        <td rowspan="1" colspan="1">8.4 [7.2, 9.7]</td>
                        <td rowspan="1" colspan="1">8.4 [7.0, 9.7]</td>
                        <td rowspan="1" colspan="1">7.9 [6.5, 9.1]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HbA1c (mmol/mol)<sup>c,d</sup></td>
                        <td rowspan="1" colspan="1">38.8 [35.5, 40.2]</td>
                        <td rowspan="1" colspan="1">37.7 [34.7, 41.0]</td>
                        <td rowspan="1" colspan="1">37.4 [34.4, 39.9]</td>
                        <td rowspan="1" colspan="1">0.027</td>
                        <td rowspan="1" colspan="1">47.5 [42.1, 56.6]</td>
                        <td rowspan="1" colspan="1">44.3 [39.9, 53.0]</td>
                        <td rowspan="1" colspan="1">43.2 [38.8, 49.7]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Fasting insulin (pmol/L)<sup>c,d</sup></td>
                        <td rowspan="1" colspan="1">262 [184, 355]</td>
                        <td rowspan="1" colspan="1">198 [144, 264]</td>
                        <td rowspan="1" colspan="1">162 [111, 227]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">330 [229, 453]</td>
                        <td rowspan="1" colspan="1">251 [172, 364]</td>
                        <td rowspan="1" colspan="1">192 [133, 266]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Triglycerides (mmol/L)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">1.6 [1.2, 2.0]</td>
                        <td rowspan="1" colspan="1">1.4 [1.0, 1.8]</td>
                        <td rowspan="1" colspan="1">1.1 [0.8, 1.5]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">1.6 [1.2, 2.3]</td>
                        <td rowspan="1" colspan="1">1.4 [1.1, 1.9]</td>
                        <td rowspan="1" colspan="1">1.2 [0.9, 1.7]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HDL-C (mmol/L)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">1.3 [1.1, 1.5]</td>
                        <td rowspan="1" colspan="1">1.3 [1.1, 1.5]</td>
                        <td rowspan="1" colspan="1">1.5 [1.2, 1.7]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">1.2 [1.0, 1.4]</td>
                        <td rowspan="1" colspan="1">1.3 [1.1, 1.5]</td>
                        <td rowspan="1" colspan="1">1.4 [1.1, 1.6]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">LDL-C (mmol/L)<sup>c,d</sup></td>
                        <td rowspan="1" colspan="1">2.9 [2.3, 3.5]</td>
                        <td rowspan="1" colspan="1">2.7 [2.2, 3.2]</td>
                        <td rowspan="1" colspan="1">2.7 [2.2, 3.2]</td>
                        <td rowspan="1" colspan="1">0.064</td>
                        <td rowspan="1" colspan="1">2.3 [1.8, 2.9]</td>
                        <td rowspan="1" colspan="1">2.4 [1.9, 3.0]</td>
                        <td rowspan="1" colspan="1">2.4 [1.9, 3.0]</td>
                        <td rowspan="1" colspan="1">0.227<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>CLINICAL</bold>
                        </td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">34 [30, 39]</td>
                        <td rowspan="1" colspan="1">31 [28, 37]</td>
                        <td rowspan="1" colspan="1">30 [26. 34]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">35 [31, 39]</td>
                        <td rowspan="1" colspan="1">34 [30, 38]</td>
                        <td rowspan="1" colspan="1">31 [27, 36]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Waist (cm)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">109 [102, 117]</td>
                        <td rowspan="1" colspan="1">106 [98, 114]</td>
                        <td rowspan="1" colspan="1">100 [92, 110]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">113 [104, 122]</td>
                        <td rowspan="1" colspan="1">110 [100, 119]</td>
                        <td rowspan="1" colspan="1">103 [94, 112]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">DBP (mm/Hg)</td>
                        <td rowspan="1" colspan="1">73 [67, 79]</td>
                        <td rowspan="1" colspan="1">71 [65, 76]</td>
                        <td rowspan="1" colspan="1">70 [63, 76]</td>
                        <td rowspan="1" colspan="1">&lt;0.001<sup>e</sup></td>
                        <td rowspan="1" colspan="1">73 [66, 79]</td>
                        <td rowspan="1" colspan="1">71 [64, 78]</td>
                        <td rowspan="1" colspan="1">70 [65, 78]</td>
                        <td rowspan="1" colspan="1">0.223</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">SBP (mm/Hg)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">119 [113, 127]</td>
                        <td rowspan="1" colspan="1">117 [110, 128]</td>
                        <td rowspan="1" colspan="1">119 [110, 130]</td>
                        <td rowspan="1" colspan="1">0.339</td>
                        <td rowspan="1" colspan="1">120 [111, 129]</td>
                        <td rowspan="1" colspan="1">120 [112, 128]</td>
                        <td rowspan="1" colspan="1">122 [112, 130]</td>
                        <td rowspan="1" colspan="1">0.127<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diabetes duration (years)</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">N/A</td>
                        <td rowspan="1" colspan="1">8 [5, 11]</td>
                        <td rowspan="1" colspan="1">9 [6, 12]</td>
                        <td rowspan="1" colspan="1">10 [6, 12]</td>
                        <td rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hypertension or on medication<sup>d</sup></td>
                        <td rowspan="1" colspan="1">78 (55.7%)</td>
                        <td rowspan="1" colspan="1">85 (49.7%)</td>
                        <td rowspan="1" colspan="1">288 (56.8%)</td>
                        <td rowspan="1" colspan="1">0.269</td>
                        <td rowspan="1" colspan="1">231 (74.0%)</td>
                        <td rowspan="1" colspan="1">166 (72.5%)</td>
                        <td rowspan="1" colspan="1">340 (72.5%)</td>
                        <td rowspan="1" colspan="1">0.878</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Metabolic syndrome<sup>d</sup></td>
                        <td rowspan="1" colspan="1">56 (39.4%)</td>
                        <td rowspan="1" colspan="1">53 (30.6%)</td>
                        <td rowspan="1" colspan="1">149 (28.3%)</td>
                        <td rowspan="1" colspan="1">0.038<sup>e</sup></td>
                        <td rowspan="1" colspan="1">215 (67.6%)</td>
                        <td rowspan="1" colspan="1">133 (56.6%)</td>
                        <td rowspan="1" colspan="1">239 (49.7%)</td>
                        <td rowspan="1" colspan="1">&lt; 0.001<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Lipid lowering agents<sup>d</sup></td>
                        <td rowspan="1" colspan="1">35 (25%)</td>
                        <td rowspan="1" colspan="1">53 (31%)</td>
                        <td rowspan="1" colspan="1">165 (32.5%)</td>
                        <td rowspan="1" colspan="1">0.232</td>
                        <td rowspan="1" colspan="1">165 (52.9%)</td>
                        <td rowspan="1" colspan="1">120 (52.4%)</td>
                        <td rowspan="1" colspan="1">260 (55.3%)</td>
                        <td rowspan="1" colspan="1">0.699</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Antihyperglycemic agents<sup>d</sup></td>
                        <td rowspan="1" colspan="1">12 (8.6%)</td>
                        <td rowspan="1" colspan="1">12 (7.0%)</td>
                        <td rowspan="1" colspan="1">20 (3.9%)</td>
                        <td rowspan="1" colspan="1">0.056<sup>e</sup></td>
                        <td rowspan="1" colspan="1">187 (59.9%)</td>
                        <td rowspan="1" colspan="1">115 (50.2%)</td>
                        <td rowspan="1" colspan="1">230 (48.9%)</td>
                        <td rowspan="1" colspan="1">0.007<sup>e</sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Retinopathy<sup>d</sup></td>
                        <td rowspan="1" colspan="1">11 (8.0%)</td>
                        <td rowspan="1" colspan="1">16 (9.5%)</td>
                        <td rowspan="1" colspan="1">45 (8.8%)</td>
                        <td rowspan="1" colspan="1">0.900</td>
                        <td rowspan="1" colspan="1">36 (11.5%)</td>
                        <td rowspan="1" colspan="1">29 (12.6%)</td>
                        <td rowspan="1" colspan="1">70 (15.0%)</td>
                        <td rowspan="1" colspan="1">0.358</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Nephropathy<sup>d</sup></td>
                        <td rowspan="1" colspan="1">9 (6.3%)</td>
                        <td rowspan="1" colspan="1">12 (6.9%)</td>
                        <td rowspan="1" colspan="1">52 (9.9%)</td>
                        <td rowspan="1" colspan="1">0.271</td>
                        <td rowspan="1" colspan="1">59 (15.5%)</td>
                        <td rowspan="1" colspan="1">45 (19.2%)</td>
                        <td rowspan="1" colspan="1">85 (17.7%)</td>
                        <td rowspan="1" colspan="1">0.496</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Neuropathy</td>
                        <td rowspan="1" colspan="1">10 (7.4%)</td>
                        <td rowspan="1" colspan="1">21 (12.7%)</td>
                        <td rowspan="1" colspan="1">51 (10.2%)</td>
                        <td rowspan="1" colspan="1">0.328</td>
                        <td rowspan="1" colspan="1">25 (8.1%)</td>
                        <td rowspan="1" colspan="1">20 (8.7%)</td>
                        <td rowspan="1" colspan="1">50 (10.8%)</td>
                        <td rowspan="1" colspan="1">0.401</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Any microangiopathy<sup>d</sup></td>
                        <td rowspan="1" colspan="1">26 (18.3%)</td>
                        <td rowspan="1" colspan="1">44 (25.4%)</td>
                        <td rowspan="1" colspan="1">132 (25.0%)</td>
                        <td rowspan="1" colspan="1">0.219</td>
                        <td rowspan="1" colspan="1">92 (28.9%)</td>
                        <td rowspan="1" colspan="1">75 (31.9%)</td>
                        <td rowspan="1" colspan="1">170 (35.3%)</td>
                        <td rowspan="1" colspan="1">0.162</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CAC (Agatston score)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">4 [0, 62]</td>
                        <td rowspan="1" colspan="1">6 [0, 198]</td>
                        <td rowspan="1" colspan="1">7 [0, 152]</td>
                        <td rowspan="1" colspan="1">0.175</td>
                        <td rowspan="1" colspan="1">13 [0, 111]</td>
                        <td rowspan="1" colspan="1">17 [0, 212]</td>
                        <td rowspan="1" colspan="1">22 [0, 182]</td>
                        <td rowspan="1" colspan="1">0.156</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">log(CAC+1)<sup>d</sup></td>
                        <td rowspan="1" colspan="1">1.6 [0, 4.1]</td>
                        <td rowspan="1" colspan="1">1.9 [0, 5.3]</td>
                        <td rowspan="1" colspan="1">2.1 [0, 5]</td>
                        <td rowspan="1" colspan="1">0.287</td>
                        <td rowspan="1" colspan="1">2.6 [0, 4.7]</td>
                        <td rowspan="1" colspan="1">2.9 [0, 5.4]</td>
                        <td rowspan="1" colspan="1">3.1 [0, 5.2]</td>
                        <td rowspan="1" colspan="1">0.288</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="fn-0104">
                      <p>Abbreviations: BMI, body mass index; CAC, coronary calcium scoring; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LA, liver attenuation; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.</p>
                    </fn>
                    <fn id="fn-0105">
                      <p><sup>a</sup><italic toggle="yes">P</italic> value for differences between LA categories within no diabetes/diabetes subgroups.</p>
                    </fn>
                    <fn id="fn-0106">
                      <p><sup>b</sup><italic toggle="yes">P</italic> value &lt; 0.05 for chi-square test of LA category prevalences in the 2 diabetes groups.</p>
                    </fn>
                    <fn id="fn-0107">
                      <p><sup>c</sup><italic toggle="yes">P</italic> value &lt; 0.05 for test of diabetes × LA interaction.</p>
                    </fn>
                    <fn id="fn-0108">
                      <p><sup>d</sup><italic toggle="yes">P</italic> value &lt; 0.05 for differences between no diabetes/diabetes subgroups (collapsed across LA categories).</p>
                    </fn>
                    <fn id="fn-0109">
                      <p><sup>e</sup><italic toggle="yes">P</italic> value &lt; 0.05 for trend test.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s10">
                <title>Baseline Predictors of Liver Attenuation</title>
                <p>Given the associations between anthropometric and metabolic factors and mean LA we then examined whether LA was predicted by these factors as well as several other biomarkers for increased liver fat that were available in DPP at entry into the study by analyzing their associations adjusted for demographics (age, sex, race), and treatment group with LA values (<xref rid="F4" ref-type="fig">Fig. 4A</xref>; Model 1). All except HbA1c and FG were associated with mean LA in an inverse manner signifying greater liver attenuation per 1 SD of the covariate, except for adiponectin and HDL-C which were directly related. After including all these variables in a single model (<xref rid="F4" ref-type="fig">Fig. 4A</xref>; Model 2), FI, DMGV, and tPA (inversely) and adiponectin (directly) remained independently associated while waist circumference did not. Individual associations with prevalence of LA &lt; 40 were similar to those for mean LA (<xref rid="F4" ref-type="fig">Fig. 4B</xref>; Model 1), with FI, tPA, adiponectin, and FG remaining associated after adjustment for other baseline covariates (<xref rid="F4" ref-type="fig">Fig. 4B</xref>; Model 1). The direction of the effects was concordant for the 2 outcomes.</p>
                <fig position="float" id="F4">
                  <label>Figure 4.</label>
                  <caption>
                    <p>Association of baseline covariates with LA levels and prevalence of LA &lt; 40 expressed as estimated differences in mean LA (Panel A, black dots with 95% CI [shaded bar]) and odds ratio for LA &lt; 40 (Panel B, black dots with 95% CI [shaded bar]) per 1 standard deviation increase in baseline covariates. Model 1 shows estimates not adjusted for other displayed baseline covariates, while estimates adjusted for all displayed baseline covariates are shown in Model 2. All displayed effects are adjusted for race, sex, age, and intervention group.</p>
                  </caption>
                  <graphic xlink:href="dgab160f0004" position="float"/>
                </fig>
              </sec>
              <sec id="s11">
                <title>Predictors of Liver Attenuation During Follow-Up</title>
                <p>Considered individually in analyses adjusting for baseline value, demographics, and treatment group, all averaged annual variables were related to mean LA (<xref rid="F5" ref-type="fig">Fig. 5A</xref>; Model 1) and LA &lt; 40 prevalence (<xref rid="F5" ref-type="fig">Fig. 5B</xref>; Model 1) with the exception of adiponectin for the LA outcome. When all baseline and averaged annual terms plus adjustment for demographics and intervention group were combined (<xref rid="F5" ref-type="fig">Figs 5A</xref> and <xref rid="F5" ref-type="fig">5B</xref>; Model 2) only waist, triglyceride, and FI remained significantly associated with the hepatic fat measures for both outcomes. Addition of diabetes status to these models did not change these associations (<xref rid="F6" ref-type="fig">Fig. 6</xref>).</p>
                <fig position="float" id="F5">
                  <label>Figure 5.</label>
                  <caption>
                    <p>Association of postrandomization covariates (average of all repeated measurements obtained after randomization until the time of the scan) with LA levels and prevalence of LA &lt; 40 expressed as estimated differences in mean LA (Panel A, black dots with 95% CI [shaded bar]) and odds ratio for LA &lt; 40 (Panel B, black dots with 95% CI [shaded bar]) per 1 standard deviation increase in follow-up–averaged covariates. Model 1shows estimates unadjusted for other displayed covariates, while Model 2 shows adjusted estimates. All displayed effects are adjusted for race, sex, age, intervention group, and baseline levels of covariates (the single covariate in Model 1 and all the covariates in Model 2).</p>
                  </caption>
                  <graphic xlink:href="dgab160f0005" position="float"/>
                </fig>
                <fig position="float" id="F6">
                  <label>Figure 6.</label>
                  <caption>
                    <p>Adjusted models of mean LA differences with 95% CI and odds ratios with 95% CI for LA &lt; 40 compared with LA ≥ 40 regressed on demographic, treatment group, and follow-up–averaged, anthropometric, and metabolic factors as in <xref rid="F5" ref-type="fig">Fig. 5</xref>, but with and without diabetes in the models.</p>
                  </caption>
                  <graphic xlink:href="dgab160f0006" position="float"/>
                </fig>
              </sec>
              <sec id="s12">
                <title>Diabetes and Liver Attenuation</title>
                <p>We then investigated whether these 3 variables, waist, FI, and triglyceride accounted for the difference in LA in those with versus without diabetes by assessing the effects of these variables on the ratios of mean LA and on the 3-category LA outcome by diabetes status. In addition, because those with diabetes had higher HbA1c values, time-averaged HbA1c was also evaluated. The models tested the added effect of each variable after adjusting for baseline values, demographics, and treatment group (<xref rid="F7" ref-type="fig">Fig. 7</xref>) by comparing the ratio of the geometric means of LA (panel A) and the odds of severe hepatic fat (LA &lt; 40:LA &gt; 50) and moderate hepatic fat (LA 40-50:LA &gt; 50) in those with versus without diabetes (panel B). Being in the diabetes group was associated with increased hepatic fat (ie, decreased mean LA ratio in panel A or increased odds of LA &lt; 40 or LA 40-50 versus &gt; 50 in panel B) for all models except LA 40 to 50 in models 4 and 6. Simultaneous adjustment for waist, FI, HbA1c, and triglycerides did not fully account for the diabetes-related differences in mean LA or odds of fatty liver (LA &lt; 40 vs &gt; 50), although they were attenuated particularly by the addition of FI to the base model.</p>
                <fig position="float" id="F7">
                  <label>Figure 7.</label>
                  <caption>
                    <p>Effects of adding adjustment for baseline and mean follow-up values for triglyceride, waist circumference, FI, and HbA1c (Model 2-5) to model 1 adjusted for age, race, sex, and treatment group, comparing mean LA (Panel A) and prevalence of LA categories (Panel B) in the diabetes vs nondiabetes groups. A final model includes adjustment for all the covariates (Model 6). Effects are expressed as the ratio of the geometric mean and 95% CI of LA (Panel A) between diabetes vs nondiabetes from a linear model with logLA as outcome. The odds ratios (95% CI) between diabetes vs nondiabetes of having LA &lt; 40 and LA 40-50 is compared to LA &gt; 50 (Panel B). The x-axis is reversed in Panel A so that values to the right of the null reference line indicate increasing hepatic fat (consistent with Panel B).</p>
                  </caption>
                  <graphic xlink:href="dgab160f0007" position="float"/>
                </fig>
              </sec>
              <sec id="s13">
                <title>Anthropometric Measures and Liver Attenuation</title>
                <p><xref rid="F8" ref-type="fig">Figure 8</xref> shows the association between mean LA and average percent changes from baseline in weight (Panel A) and waist until the time of the scan (Panel B) adjusted for demographic and metabolic factors and by diabetes status. Both waist and weight change were strongly and inversely related to mean LA in participants with or without diabetes.</p>
                <fig position="float" id="F8">
                  <label>Figure 8.</label>
                  <caption>
                    <p>Relationships among LA, diabetes status, and percent change from randomization to the year of the scan in weight (Panel A) and waist circumference (Panel B). Figures present expected mean LA and associated 95% confidence interval for different percent changes in waist and weight estimated from a linear model. Analyses were adjusted for demographic factors, interventions, and baseline and time-averaged FI, triglyceride, HbA1c, and year 1 adiponectin.</p>
                  </caption>
                  <graphic xlink:href="dgab160f0008" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec id="s14">
              <title>Discussion</title>
              <p>In this cohort of DPP/DPPOS participants with prediabetes at entry into the trial, we found that 25% of the population had a fatty liver when assessed 14 years later, at which time 56% had developed diabetes using the cutpoint of LA &lt; 40 by CT (<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0012" ref-type="bibr">12</xref>). As a comparison, the prevalence of LA &lt; 40 in 3357 asymptomatic individuals being screened for colon cancer was 6.2% (<xref rid="CIT0014" ref-type="bibr">14</xref>) and in the Multiethnic Ethnic Study of Atherosclerosis (MESA), a population-based study, the prevalence of fatty liver using the LA &lt; 40 cutpoint was 6.7% (<xref rid="CIT0015" ref-type="bibr">15</xref>). Compared with these populations who were not specifically selected for the presence of higher BMI and glucose intolerance as we did in DPP, the DPPOS cohort had a considerably higher prevalence of fatty liver. These findings were undoubtedly influenced by those who had developed diabetes at the time of the scan, 31% of whom had LA &lt; 40, compared with 17% of those who had not. The prevalence of fatty liver in those with diabetes in MESA was 24% (<xref rid="CIT0015" ref-type="bibr">15</xref>), based on a liver/spleen ratio of &lt;1.0 so our findings are not dissimilar. Although the mean duration of diabetes in the diabetes inception cohort in DPPOS was 7.4 to 9.1 years, this should be viewed in the context of time following biochemical diagnosis assessed semi-annually in this study rather than that in clinically diagnosed diabetes which is usually made years later, indicating that fatty liver is prevalent early in the course of diabetes. The results further demonstrate that even those without diabetes in our study, most of whom had persisting prediabetes, had a higher prevalence of fatty liver than that reported in the general population.</p>
              <p>African Americans in DPPOS had a lower prevalence of fatty liver than non-Hispanic Whites, as noted in the Dallas Heart Study, in which hepatic fat was measured in a large urban population using proton magnetic resonance spectroscopy (<xref rid="CIT0016" ref-type="bibr">16</xref>) and which was shown to be in part due to the increased frequency of a genetic polymorphism in African Americans associated with lower hepatic fat (<xref rid="CIT0017" ref-type="bibr">17</xref>). It is of interest in this regard that despite having lower hepatic fat measurements as well as a lower prevalence of LA &lt; 40, there were no differences in rates of diabetes development in DPP between African Americans and non-Hispanic Whites or Hispanic participants (<xref rid="CIT0006" ref-type="bibr">6</xref>). It was also notable that in our study there were no significant differences in hepatic fat between non-Hispanic White, Hispanic, or Asian American subjects, unlike the results reported in the Dallas Heart Study as well as in MESA (<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>). This discrepancy may have resulted from the per protocol selection of the DPP cohort for a narrow range of glucose intolerance, more limited BMI range, and a smaller sample size for Asians. Since glucose intolerance is more common among minority race/ethnic groups in the general population, this may contribute to population-based race/ethnicity differences in hepatic fat compared with a cohort primarily selected for obesity and glucose intolerance. Despite this, we found that American Indians had a greater prevalence of fatty liver than did non-Hispanic Whites, an observation that to our knowledge has not previously been reported. Although we observed no differences by sex, the finding of an age trend toward higher LA and a lower prevalence of LA &lt; 40 consistent with lower hepatic fat with aging confirms a previous report (<xref rid="CIT0019" ref-type="bibr">19</xref>). It was of interest that despite their greater degree of liver fat, these age and race/ethnicity differences were also present in those with diabetes (data not shown).</p>
              <p>We found no overall differences in liver fat measures between lifestyle or metformin interventions and placebo treatment. Although a major focus of the lifestyle intervention was to achieve persistent weight loss (<xref rid="CIT0005" ref-type="bibr">5</xref>) and weight reduction has been shown to decrease hepatic fat in small studies (<xref rid="CIT0020" ref-type="bibr">20</xref>), at the time of the scan there were no significant weight differences between the 3 intervention groups, probably because of the introduction of group lifestyle to the entire cohort in the DPPOS phase. However, there was a strong linear relationship between mean LA and waist or weight change independent of metabolic variables and treatment group over time, supporting an important role for weight reduction in these overweight individuals with glucose intolerance in reducing hepatic steatosis. The finding that long-term metformin treatment had no overall apparent effect on hepatic fat is consistent with previous reports (<xref rid="CIT0021" ref-type="bibr">21</xref>) although the finding of a treatment group by diabetes status interaction for mean LA and LA &lt; 40 raises the possibility that metformin may have different effects on liver fat in those with versus without diabetes.</p>
              <p>We showed, as others have, that there was a graded relationship between glycemia, insulin resistance as measured by the FI, BMI, and waist circumference, and triglyceride and HDL-C values all assessed during the year of scanning and the amount of hepatic fat by LA categories (<xref rid="CIT0002" ref-type="bibr">2</xref>). Furthermore, for any given LA category, the presence of diabetes was associated with greater cardiometabolic disturbance compared with those without diabetes. The fact that we were not able to find an association between LA category and presence of microangiopathy may reflect its low prevalence and severity in this study, and the lack of association with CAC as an index of subclinical coronary heart disease has been reported by others (<xref rid="CIT0022" ref-type="bibr">22</xref>).</p>
              <p>Since these cardiometabolic risk factors had been assessed yearly from entry into the study approximately 14 years before the scan and in addition several other biomarkers of hepatic steatosis, namely adiponectin (<xref rid="CIT0024" ref-type="bibr">24</xref>), tPA (as a surrogate for PAI-1[<xref rid="CIT0025" ref-type="bibr">25</xref>]), CRP (<xref rid="CIT0026" ref-type="bibr">26</xref>), and DMGV (<xref rid="CIT0011" ref-type="bibr">11</xref>) were also measured at baseline and for adiponectin, tPA, and CRP at year 1 and repeated at DPPOS year 1 for tPA and CRP and year 5 for CRP, it was possible to test these variables for their long-term associations with hepatic fat. The association of baseline FI as a measure of insulin resistance, adiponectin, tPA and DMGV with mean LA independent of level of glycemia and other cardiometabolic risk factors measured approximately 14 years later indicates that these are important markers of future hepatic fat accumulation in subjects with glucose intolerance and that the metabolic milieu favoring hepatic fat accumulation develops early in the course of dysglycemia. When fully adjusted average follow-up values of the measured metabolic variables were assessed, FI remained associated but adiponectin, tPA, and DMGV values were no longer significant, although this may have been due to the limited number of follow-up measurements performed for these analytes. Instead, average triglyceride and waist circumference values measured over time, 2 commonly measured clinical tests that have been associated with increased visceral fat (<xref rid="CIT0027" ref-type="bibr">27</xref>), were independently related to LA. The fact that waist circumference was not independently associated with hepatic fat at baseline raises the possibility that changes in body fat closer to the time of the scan are more strongly related to the amount of hepatic fat.</p>
              <p>The finding that the degree of insulin resistance, level of triglyceride, and waist size averaged over a lengthy follow-up period were each independently associated with the amount of liver fat in a large, diverse cohort with glucose intolerance suggests that these 3 factors were linked to the relatively high prevalence of fatty liver in this population. The basis for these associations is complex, especially for insulin resistance where there is evidence for both cause and effect relationships in that insulin resistance facilitates hepatic fat deposition, while increased liver fat content leads to hepatic insulin resistance (<xref rid="CIT0002" ref-type="bibr">2</xref>). A stronger argument may be made that the association between triglyceride and liver fat reflects the effect of increased liver fat on very-low-density lipoprotein production, leading to an increase in plasma triglyceride concentrations (<xref rid="CIT0028" ref-type="bibr">28</xref>). However, this interpretation is also complicated by evidence that several genetic polymorphisms that increase the prevalence of fatty liver are not associated with increased triglyceride levels, possibly because of defects in hepatic triglyceride export (<xref rid="CIT0017" ref-type="bibr">17</xref>, <xref rid="CIT0029" ref-type="bibr">29</xref>). It is very likely that time-related weight change is a causative factor for increased liver fat (<xref rid="CIT0020" ref-type="bibr">20</xref>).</p>
              <p>We also found that although average FG and HbA1c in individual analyses were associated with liver fat, this was no longer true when insulin, waist, and triglyceride were included in multivariable models, indicating that progression of dysglycemia per se was not a major correlate of fatty liver in our study, in contrast to reports of others, perhaps because of the truncated range of values predetermined by eligibility for DPP and the relatively modest degrees of hyperglycemia in our cohort. Furthermore, inclusion of diabetes status in the model did not alter these associations. Also contrary to expectations, diabetes duration was associated with lower hepatic fat, although this effect was small. However, despite these strong associations, these metabolic factors only partly accounted for the greater degree of liver fat in diabetes, pointing to the importance of other factors not assessed here (<xref rid="CIT0001" ref-type="bibr">1</xref>).</p>
              <p>As noted above, a limitation of the study is the absence of liver fat assessment at baseline, since there may have been differences by treatment assignment at entry. Also, the lack of follow-up adiponectin, tPA, and DMGV measurements prevented an adequate assessment of the importance of changes in these biomarkers over time on liver fat. The strengths of the study include the large, multiethnic, carefully selected cohort, the richness of the dataset, the prospective ascertainment of diabetes, and the randomized treatments.</p>
              <p>In conclusion, the DPP/DPPOS data demonstrate that fatty liver was prevalent in a population with prediabetes who had been followed for 14 years, during which time 56% developed diabetes, and that fatty liver was almost twice as common as in those with diabetes versus those with persisting prediabetes. Annually averaged measures of waist circumference, insulin resistance, and triglycerides, but not worsening glycemia over the course of the study were independently associated with fatty liver prevalence and accounted for some but not all of the difference between fatty liver prevalence in those with versus without diabetes. Given the published evidence of the risks for progression of NAFLD to nonalcoholic steatohepatitis and cirrhosis in diabetes (<xref rid="CIT0030" ref-type="bibr">30-32</xref>), and its association with the development of micro- and macrovascular disease (<xref rid="CIT0033" ref-type="bibr">33</xref>, <xref rid="CIT0034" ref-type="bibr">34</xref>), these findings raise the importance of early recognition of the presence of NAFLD in those with prediabetes.</p>
            </sec>
          </body>
          <back>
            <ack id="a1">
              <title>Acknowledgments</title>
              <p>The Research Group gratefully acknowledges the commitment and dedication of the participants of the DPP and DPPOS. Dr. Gerszten is supported by grant DK081572. Dr. Gerszten is supported by grant DK081572.</p>
              <p>* Principal Investigator</p>
              <p>** Program Coordinator</p>
            </ack>
            <glossary>
              <def-list>
                <title>Abbreviations</title>
                <def-item>
                  <term>BMI</term>
                  <def>
                    <p>body mass index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BP</term>
                  <def>
                    <p>blood pressure</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CAC</term>
                  <def>
                    <p>coronary calcium scoring</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CRP</term>
                  <def>
                    <p>high-sensitivity C-reactive protein</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CT</term>
                  <def>
                    <p>computed tomography</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DMGV</term>
                  <def>
                    <p>dimethylguanidinovaleric acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DPP</term>
                  <def>
                    <p>Diabetes Prevention Program</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DPPOS</term>
                  <def>
                    <p>Diabetes Prevention Program Outcome Study</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FG</term>
                  <def>
                    <p>fasting plasma glucose</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FI</term>
                  <def>
                    <p>fasting insulin</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HbA1c</term>
                  <def>
                    <p>glycated hemoglobin A1c</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HDL-C</term>
                  <def>
                    <p>high-density lipoprotein cholesterol</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HU</term>
                  <def>
                    <p>Hounsfield units</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IGT</term>
                  <def>
                    <p>impaired glucose tolerance</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LA</term>
                  <def>
                    <p>liver attenuation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LDL-C</term>
                  <def>
                    <p>low-density lipoprotein cholesterol</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MESA</term>
                  <def>
                    <p>Multiethnic Ethnic Study of Atherosclerosis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NAFLD</term>
                  <def>
                    <p>nonalcoholic fatty liver disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ROI</term>
                  <def>
                    <p>region of interest</p>
                  </def>
                </def-item>
                <def-item>
                  <term>tPA</term>
                  <def>
                    <p>tissue plasminogen activator</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <sec id="s0106">
              <title>Pennington Biomedical Research Center (Baton Rouge, LA)</title>
              <p>George A. Bray, MD*</p>
              <p>Kishore Gadde, MD*</p>
              <p>Iris W. Culbert, BSN, RN, CCRC**</p>
              <p>Jennifer Arceneaux RN, BSN**</p>
              <p>Annie Chatellier, RN, CCRC**</p>
              <p>Amber Dragg RD, LDN**</p>
              <p>Catherine M. Champagne, PhD, RD</p>
              <p>Crystal Duncan, LPN</p>
              <p>Barbara Eberhardt, RD, LDN</p>
              <p>Frank Greenway, MD</p>
              <p>Fonda G. Guillory, LPN</p>
              <p>April A. Herbert, RD</p>
              <p>Michael L. Jeffirs, LPN</p>
              <p>Betty M. Kennedy, MPA</p>
              <p>Erma Levy, RD</p>
              <p>Monica Lockett, LPN</p>
              <p>Jennifer C. Lovejoy, PhD</p>
              <p>Laura H. Morris, BS</p>
              <p>Lee E. Melancon, BA, BS</p>
              <p>Donna H. Ryan, MD</p>
              <p>Deborah A. Sanford, LPN</p>
              <p>Kenneth G. Smith, BS, MT</p>
              <p>Lisa L. Smith, BS</p>
              <p>Julia A. St.Amant, RTR</p>
              <p>Richard T. Tulley, PhD</p>
              <p>Paula C. Vicknair, MS, RD</p>
              <p>Donald Williamson, PhD</p>
              <p>Jeffery J. Zachwieja, PhD</p>
            </sec>
            <sec id="s0107">
              <title>University of Chicago (Chicago, IL)</title>
              <p>Kenneth S. Polonsky, MD*</p>
              <p>Janet Tobian, MD, PhD*</p>
              <p>David A. Ehrmann, MD*</p>
              <p>Margaret J. Matulik, RN, BSN**</p>
              <p>Bart Clark, MD</p>
              <p>Kirsten Czech, MS</p>
              <p>Catherine DeSandre, BA</p>
              <p>Ruthanne Hilbrich, RD</p>
              <p>Wylie McNabb, EdD</p>
              <p>Ann R. Semenske, MS, RD</p>
            </sec>
            <sec id="s0108">
              <title>Jefferson Medical College (Philadelphia, PA)</title>
              <p>Jose F. Caro, MD*</p>
              <p>Kevin Furlong, DO*</p>
              <p>Barry J. Goldstein, MD, PhD*</p>
              <p>Pamela G. Watson, RN, ScD*</p>
              <p>Kellie A. Smith, RN, MSN**</p>
              <p>Jewel Mendoza, RN, BSN**</p>
              <p>Wendi Wildman, RN**</p>
              <p>Renee Liberoni, MPH</p>
              <p>John Spandorfer, MD</p>
              <p>Constance Pepe, MS, RD</p>
            </sec>
            <sec id="s0109">
              <title>University of Miami (Miami, FL)</title>
              <p>Richard P. Donahue, PhD*</p>
              <p>Ronald B. Goldberg, MD*</p>
              <p>Ronald Prineas, MD, PhD*</p>
              <p>Jeanette Calles, MSEd**</p>
              <p>Juliet Ojito, RN**</p>
              <p>Patricia Rowe, MPA**</p>
              <p>Paul Cassanova-Romero, MD</p>
              <p>Sumaya Castillo-Florez, MPH</p>
              <p>Hermes J. Florez, MD</p>
              <p>Anna Giannella, RD, MS**</p>
              <p>Lascelles Kirby, MS</p>
              <p>Carmen Larreal</p>
              <p>Olga Lara</p>
              <p>Valerie McLymont, RN</p>
              <p>Jadell Mendez</p>
              <p>Arlette Perry, PhD</p>
              <p>Patrice Saab, PhD</p>
              <p>Beth Veciana</p>
            </sec>
            <sec id="s0110">
              <title>The University of Texas Health Science Center (San Antonio, TX)</title>
              <p>Steven M. Haffner, MD, MPH*</p>
              <p>Helen P. Hazuda, PhD*</p>
              <p>Maria G. Montez, RN, MSHP, CDE**</p>
              <p>Kathy Hattaway, RD, MS</p>
              <p>Carlos Lorenzo, MD, PhD</p>
              <p>Arlene Martinez, RN, BSN, CDE</p>
              <p>Tatiana Walker, RD, MS, CDE</p>
            </sec>
            <sec id="s0111">
              <title>University of Colorado (Denver, CO)</title>
              <p>Dana Dabelea, MD, PhD*</p>
              <p>Richard F. Hamman, MD, DrPH*</p>
              <p>Patricia V. Nash, MS**</p>
              <p>Sheila C. Steinke, MS**</p>
              <p>Lisa Testaverde, MS**</p>
              <p>Denise R. Anderson, RN, BSN</p>
              <p>Larry B. Ballonoff, MD</p>
              <p>Alexis Bouffard, MA, RN, BSN</p>
              <p>Brian Bucca OD, FAOO</p>
              <p>B. Ned Calonge, MD, MPH</p>
              <p>Lynne Delve</p>
              <p>Martha Farago, RN</p>
              <p>James O. Hill, PhD</p>
              <p>Shelley R. Hoyer, BS</p>
              <p>Tonya Jenkins, RD, CDE</p>
              <p>Bonnie T. Jortberg, MS, RD, CDE</p>
              <p>Dione Lenz, RN, BSN, CDE</p>
              <p>Marsha Miller, MS, RD</p>
              <p>Leigh Perreault, MD</p>
              <p>David W. Price, MD</p>
              <p>Judith G. Regensteiner, PhD</p>
              <p>Helen Seagle, MS, RD</p>
              <p>Carissa M. Smith, BS</p>
              <p>Brent VanDorsten, PhD</p>
            </sec>
            <sec id="s0112">
              <title>Joslin Diabetes Center (Boston, MA)</title>
              <p>Edward S. Horton, MD*</p>
              <p>Kathleen E. Lawton, RN**</p>
              <p>Catherine S. Poirier, RN, BSN**</p>
              <p>Kati Swift, RN, BSN**</p>
              <p>Ronald A. Arky, MD</p>
              <p>Marybeth Bryant</p>
              <p>Jacqueline P. Burke, BSN</p>
              <p>Enrique Caballero, MD</p>
              <p>Karen M. Callaphan, BA</p>
              <p>Barbara Fargnoli, RD</p>
              <p>Therese Franklin</p>
              <p>Om P. Ganda, MD</p>
              <p>Ashley Guidi, BS</p>
              <p>Mathew Guido, BA</p>
              <p>Sharon D. Jackson, MS, RD, CDE</p>
              <p>Alan M. Jacobsen, MD</p>
              <p>Lori Lambert, MS, RD, LD</p>
              <p>Sarah Ledbury, Med, RD</p>
              <p>Margaret Kocal, RN, CDE</p>
              <p>Lyn M. Kula, RD</p>
              <p>Maureen A. Malloy, BS</p>
              <p>Maryanne Nicosia, MS, RD</p>
              <p>Cathryn F. Oldmixon, RN</p>
              <p>Jocelyn Pan, BS, MPH</p>
              <p>Marizel Quitingon</p>
              <p>Stacy Rubtchinsky, BS</p>
              <p>Jessica Sansoucy, BS</p>
              <p>Dana Schweizer, BSN</p>
              <p>Ellen W. Seely, MD</p>
              <p>Donald Simonson, MD</p>
              <p>Fannie Smith, MD</p>
              <p>Caren G. Solomon, MD, MPH</p>
              <p>Jeanne Spellman, RD</p>
              <p>James Warram, MD</p>
            </sec>
            <sec id="s0113">
              <title>VA Puget Sound Health Care System and University of Washington (Seattle, WA)</title>
              <p>Steven E. Kahn, MB, ChB*</p>
              <p>Brenda K. Montgomery, RN, BSN, CDE**</p>
              <p>Wilfred Fujimoto, MD</p>
              <p>Robert H. Knopp, MD</p>
              <p>Edward W. Lipkin, MD</p>
              <p>Michelle Marr, BA</p>
              <p>Ivy Morgan-Taggart</p>
              <p>Anne Murillo, BS</p>
              <p>Dace Trence, MD</p>
              <p>Lonnese Taylor, RN, BS</p>
              <p>April Thomas, RD, MPH, CDE</p>
              <p>Elaine C. Tsai, MD, MPH</p>
            </sec>
            <sec id="s0114">
              <title>University of Tennessee (Memphis, TN)</title>
              <p>Samuel Dagogo-Jack, MD, MSc, FRCP, FACP*</p>
              <p>Abbas E. Kitabchi, PhD, MD, FACP*</p>
              <p>Mary E. Murphy, RN, MS, CDE, MBA**</p>
              <p>Laura Taylor, RN, BSN, CDE**</p>
              <p>Jennifer Dolgoff, RN, BSN**</p>
              <p>William B. Applegate, MD, MPH</p>
              <p>Michael Bryer-Ash, MD</p>
              <p>Debra Clark, LPN</p>
              <p>Sandra L. Frieson, RN</p>
              <p>Uzoma Ibebuogu, MD</p>
              <p>Raed Imseis, MD</p>
              <p>Helen Lambeth, RN, BSN</p>
              <p>Lynne C. Lichtermann, RN, BSN</p>
              <p>Hooman Oktaei, MD</p>
              <p>Harriet Ricks</p>
              <p>Lily M.K. Rutledge, RN, BSN</p>
              <p>Amy R. Sherman, RD, LD</p>
              <p>Clara M. Smith, RD, MHP, LDN</p>
              <p>Judith E. Soberman, MD</p>
              <p>Beverly Williams-Cleaves, MD</p>
            </sec>
            <sec id="s0115">
              <title>Northwestern University’s Feinberg School of Medicine (Chicago, IL)</title>
              <p>Boyd E. Metzger, MD*</p>
              <p>Mark E. Molitch, MD*</p>
              <p>Mariana K. Johnson, MS, RN**</p>
              <p>Daphne T. Adelman, MBA, RN</p>
              <p>Catherine Behrends</p>
              <p>Michelle Cook, MS</p>
              <p>Marian Fitzgibbon, PhD</p>
              <p>Mimi M. Giles, MS, RD</p>
              <p>Deloris Heard, MA</p>
              <p>Cheryl K.H. Johnson, MS, RN</p>
              <p>Diane Larsen, BS</p>
              <p>Anne Lowe, BS</p>
              <p>Megan Lyman, BS</p>
              <p>David McPherson, MD</p>
              <p>Samsam C. Penn, BA</p>
              <p>Thomas Pitts, MD</p>
              <p>Renee Reinhart, RN, MS</p>
              <p>Susan Roston, RN, RD</p>
              <p>Pamela A. Schinleber, RN, MS</p>
            </sec>
            <sec id="s0116">
              <title>Massachusetts General Hospital (Boston, MA)</title>
              <p>David M. Nathan, MD*</p>
              <p>Charles McKitrick, BSN**</p>
              <p>Heather Turgeon, BSN**</p>
              <p>Mary Larkin, MSN**</p>
              <p>Kathy Abbott</p>
              <p>Ellen Anderson, MS, RD</p>
              <p>Laurie Bissett, MS, RD</p>
              <p>Kristy Bondi, BS</p>
              <p>Enrico Cagliero, MD</p>
              <p>Jose C. Florez, MD, PhD+</p>
              <p>Kali D’Anna</p>
              <p>Linda Delahanty, MS, RD</p>
              <p>Valerie Goldman, MS, RD</p>
              <p>Peter Lou, MD</p>
              <p>Alexandra Poulos</p>
              <p>Elyse Raymond, BS</p>
              <p>Christine Stevens, RN</p>
              <p>Beverly Tseng</p>
            </sec>
            <sec id="s0117">
              <title>University of California San Diego (La Jolla, CA)</title>
              <p>Jerrold M. Olefsky, MD*</p>
              <p>Elizabeth Barrett-Connor, MD*</p>
              <p>Mary Lou Carrion-Petersen, RN, BSN**</p>
              <p>Madeline Beltran, RN, BSN, CDE</p>
              <p>Lauren N. Claravall, BS</p>
              <p>Jonalle M. Dowden, BS</p>
              <p>Steven V. Edelman, MD</p>
              <p>Robert R. Henry, MD</p>
              <p>Javiva Horne, RD</p>
              <p>Marycie Lamkin, RN</p>
              <p>Simona Szerdi Janesch, BA</p>
              <p>Diana Leos</p>
              <p>Sunder Mudaliar, MD</p>
              <p>William Polonsky, PhD</p>
              <p>Jean Smith, RN</p>
              <p>Jennifer Torio-Hurley</p>
              <p>Karen Vejvoda, RN, BSN, CDE, CCRC</p>
            </sec>
            <sec id="s0118">
              <title>Columbia University (New York, NY)</title>
              <p>F. Xavier Pi-Sunyer, MD*</p>
              <p>Jane E. Lee, MS**</p>
              <p>David B. Allison, PhD</p>
              <p>Nnenna Agharanya</p>
              <p>Nancy J. Aronoff, MS, RD</p>
              <p>Maria Baldo</p>
              <p>Jill P. Crandall, MD</p>
              <p>Sandra T. Foo, MD</p>
              <p>Susan Hagamen, MS, RN, CDE</p>
              <p>Jose A. Luchsinger, MD, MPH</p>
              <p>Carmen Pal, MD</p>
              <p>Kathy Parkes, RN</p>
              <p>Mary Beth Pena, RN</p>
              <p>Ellen S. Rooney, BA</p>
              <p>Gretchen E.H. Van Wye, MA</p>
              <p>Kristine A. Viscovich, ANP</p>
            </sec>
            <sec id="s0119">
              <title>Indiana University (Indianapolis, IN)</title>
              <p>David G. Marrero, PhD*</p>
              <p>Kieren J. Mather, MD*</p>
              <p>Melvin J. Prince, MD*</p>
              <p>Susie M. Kelly, RN, CDE**</p>
              <p>Marcia A. Jackson**</p>
              <p>Gina McAtee**</p>
              <p>Paula Putenney, RN**</p>
              <p>Ronald T. Ackermann, MD</p>
              <p>Carolyn M. Cantrell</p>
              <p>Yolanda F. Dotson, BS</p>
              <p>Edwin S. Fineberg, MD</p>
              <p>Megan Fultz</p>
              <p>John C. Guare, PhD</p>
              <p>Angela Hadden</p>
              <p>James M. Ignaut, MA</p>
              <p>Marion S. Kirkman, MD</p>
              <p>Erin O’Kelly Phillips</p>
              <p>Beverly D. Porter, MSN</p>
              <p>Paris J. Roach, MD</p>
              <p>Nancy D. Rowland, BS, MS</p>
              <p>Madelyn L. Wheeler, RD</p>
            </sec>
            <sec id="s0120">
              <title>Medstar Research Institute (Washington, DC)</title>
              <p>Vanita Aroda, MD*</p>
              <p>Robert E. Ratner, MD*</p>
              <p>Gretchen Youssef, RD, CDE**</p>
              <p>Sue Shapiro, RN, BSN, CCRC**</p>
              <p>Catherine Bavido-Arrage, MS, RD, LD</p>
              <p>Geraldine Boggs, MSN, RN</p>
              <p>Marjorie Bronsord, MS, RD, CDE</p>
              <p>Ernestine Brown</p>
              <p>Wayman W. Cheatham, MD</p>
              <p>Susan Cola</p>
              <p>Cindy Evans</p>
              <p>Peggy Gibbs</p>
              <p>Tracy Kellum, MS, RD, CDE</p>
              <p>Renee Wiggins, RD</p>
              <p>Milvia Lagarda</p>
              <p>Lilia Leon</p>
              <p>Claresa Levatan, MD</p>
              <p>Milajurine Lindsay</p>
              <p>Asha K. Nair, BS</p>
              <p>Maureen Passaro, MD</p>
              <p>Angela Silverman</p>
              <p>Gabriel Uwaifo, MD</p>
              <p>Debra Wells-Thayer, NP, CDE</p>
            </sec>
            <sec id="s0121">
              <title>University of Southern California/UCLA Research Center (Alhambra, CA)</title>
              <p>Mohammed F. Saad, MD*</p>
              <p>Karol Watson, MD*</p>
              <p>Maria Budget**</p>
              <p>Sujata Jinagouda, MD**</p>
              <p>Medhat Botrous, MD**</p>
              <p>Khan Akbar, MD</p>
              <p>Claudia Conzues</p>
              <p>Perpetua Magpuri</p>
              <p>Kathy Ngo</p>
              <p>Amer Rassam, MD</p>
              <p>Debra Waters</p>
              <p>Kathy Xapthalamous</p>
            </sec>
            <sec id="s0122">
              <title>Washington University (St. Louis, MO)</title>
              <p>Julio V. Santiago, MD*</p>
              <p>Samuel Dagogo-Jack, MD, MSc, FRCP, FACP*</p>
              <p>Neil H. White, MD, CDE*</p>
              <p>Angela L. Brown, MD*</p>
              <p>Samia Das, MS, MBA, RD, LD**</p>
              <p>Prajakta Khare-Ranade, MSc, RDN, LD**</p>
              <p>Tamara Stich, RN, MSN, CDE**</p>
              <p>Ana Santiago, RN</p>
              <p>Edwin Fisher, PhD</p>
              <p>Emma Hurt, RN</p>
              <p>Tracy Jones, RN</p>
              <p>Michelle Kerr, RD</p>
              <p>Lucy Ryder, RN</p>
              <p>Cormarie Wernimont, RD, LD</p>
            </sec>
            <sec id="s0123">
              <title>Johns Hopkins School of Medicine (Baltimore, MD)</title>
              <p>Sherita Hill Golden, MD, MHS, FAHA*</p>
              <p>Christopher D. Saudek, MD*</p>
              <p>Vanessa Bradley, BA**</p>
              <p>Emily Sullivan, MEd, RN**</p>
              <p>Tracy Whittington, BS**</p>
              <p>Caroline Abbas</p>
              <p>Adrienne Allen</p>
              <p>Frederick L. Brancati, MD, MHS</p>
              <p>Sharon Cappelli</p>
              <p>Jeanne M. Clark, MD</p>
              <p>Jeanne B. Charleston, RN, MSN</p>
              <p>Janice Freel</p>
              <p>Katherine Horak, RD</p>
              <p>Alicia Greene</p>
              <p>Dawn Jiggetts</p>
              <p>Deloris Johnson</p>
              <p>Hope Joseph</p>
              <p>Kimberly Loman</p>
              <p>Henry Mosley</p>
              <p>John Reusing</p>
              <p>Richard R. Rubin, PhD</p>
              <p>Alafia Samuels, MD</p>
              <p>Thomas Shields</p>
              <p>Shawne Stephens</p>
              <p>Kerry J. Stewart, EdD</p>
              <p>LeeLana Thomas</p>
              <p>Evonne Utsey</p>
              <p>Paula Williamson</p>
            </sec>
            <sec id="s0124">
              <title>University of New Mexico (Albuquerque, NM)</title>
              <p>David S. Schade, MD*</p>
              <p>Karwyn S. Adams, RN, MSN**</p>
              <p>Janene L. Canady, RN, CDE**</p>
              <p>Carolyn Johannes, RN, CDE**</p>
              <p>Claire Hemphill, RN, BSN**</p>
              <p>Penny Hyde, RN, BSN**</p>
              <p>Leslie F. Atler, PhD</p>
              <p>Patrick J. Boyle, MD</p>
              <p>Mark R. Burge, MD</p>
              <p>Lisa Chai, RN</p>
              <p>Kathleen Colleran, MD</p>
              <p>Ysela Gonzales</p>
              <p>Doris A. Hernandez-McGinnis</p>
              <p>Patricia Katz, LPN</p>
              <p>Carolyn King, Med</p>
              <p>Amer Rassam, MD</p>
              <p>Sofya Rubinchik, MD</p>
              <p>Willette Senter, RD</p>
              <p>Debra Waters, PhD</p>
            </sec>
            <sec id="s0125">
              <title>Albert Einstein College of Medicine (Bronx, NY)</title>
              <p>Jill Crandall, MD*</p>
              <p>Harry Shamoon, MD*</p>
              <p>Janet O. Brown, RN, MPH, MSN**</p>
              <p>Gilda Trandafirescu, MD**</p>
              <p>Elsie Adorno, BS</p>
              <p>Liane Cox, MS, RD</p>
              <p>Helena Duffy, MS, C-ANP</p>
              <p>Samuel Engel, MD</p>
              <p>Allison Friedler, BS</p>
              <p>Angela Goldstein, FNP-C, NPP, CSW</p>
              <p>Crystal J. Howard-Century, MA</p>
              <p>Jennifer Lukin, BA</p>
              <p>Stacey Kloiber, RN</p>
              <p>Nadege Longchamp, LPN</p>
              <p>Helen Martinez, RN, MSN, FNP-C</p>
              <p>Dorothy Pompi, BA</p>
              <p>Jonathan Scheindlin, MD</p>
              <p>Elissa Violino, RD, MS</p>
              <p>Elizabeth A. Walker PhD, RN</p>
              <p>Judith Wylie-Rosett, EdD, RD</p>
              <p>Elise Zimmerman, RD, MS</p>
              <p>Joel Zonszein, MD</p>
            </sec>
            <sec id="s0126">
              <title>University of Pittsburgh (Pittsburgh, PA)</title>
              <p>Trevor Orchard, MD*</p>
              <p>Rena R. Wing, PhD*</p>
              <p>Susan Jeffries, RN, MSN**</p>
              <p>Gaye Koenning, MS, RD**</p>
              <p>M. Kaye Kramer, BSN, MPH**</p>
              <p>Marie Smith, RN, BSN**</p>
              <p>Susan Barr, BS</p>
              <p>Catherine Benchoff</p>
              <p>Miriam Boraz, PhD</p>
              <p>Lisa Clifford, BS</p>
              <p>Rebecca Culyba, BS</p>
              <p>Marlene Frazier</p>
              <p>Ryan Gilligan, BS</p>
              <p>Stephanie Guimond, BS</p>
              <p>Susan Harrier, MLT</p>
              <p>Louann Harris, RN</p>
              <p>Andrea Kriska, PhD</p>
              <p>Qurashia Manjoo, MD</p>
              <p>Monica Mullen, MHP, RD</p>
              <p>Alicia Noel, BS</p>
              <p>Amy Otto, PhD</p>
              <p>Jessica Pettigrew, CMA</p>
              <p>Debra Rubinstein, MD</p>
              <p>Linda Semler, MS, RD</p>
              <p>Cheryl F. Smith, PhD</p>
              <p>Elizabeth Venditti, PhD</p>
              <p>Valarie Weinzierl, MPH</p>
              <p>Katherine V. Williams, MD, MPH</p>
              <p>Tara Wilson, BA</p>
            </sec>
            <sec id="s0127">
              <title>University of Hawaii (Honolulu, HI)</title>
              <p>Richard F. Arakaki, MD*</p>
              <p>Renee W. Latimer, BSN, MPH** Narleen K. Baker-Ladao, BS**</p>
              <p>Mae K. Isonaga, RD, MPH**</p>
              <p>Ralph Beddow, MD</p>
              <p>Nina E. Bermudez, MS</p>
              <p>Lorna Dias, AA</p>
              <p>Jillian Inouye, RN, PhD</p>
              <p>Marjorie K. Mau, MD</p>
              <p>John S. Melish, MD</p>
              <p>Kathy Mikami, BS, RD</p>
              <p>Pharis Mohideen, MD</p>
              <p>Sharon K. Odom, RD, MPH</p>
              <p>Raynette U. Perry, AA</p>
              <p>Robin E. Yamamoto, CDE, RD</p>
            </sec>
            <sec id="s0128">
              <title>Southwest American Indian Centers (Phoenix, AZ; Shiprock, NM; Zuni, NM)</title>
              <p>William C. Knowler, MD, DrPH*+</p>
              <p>Norman Cooeyate**</p>
              <p>Mary A. Hoskin, RD, MS**</p>
              <p>Carol A. Percy, RN, MS**</p>
              <p>Alvera Enote**</p>
              <p>Camille Natewa**</p>
              <p>Kelly J. Acton, MD, MPH</p>
              <p>Vickie L. Andre, RN, FNP</p>
              <p>Rosalyn Barber</p>
              <p>Shandiin Begay, MPH</p>
              <p>Peter H. Bennett, MB, FRCP</p>
              <p>Mary Beth Benson, RN, BSN</p>
              <p>Evelyn C. Bird, RD, MPH</p>
              <p>Brenda A. Broussard, RD, MPH, MBA, CDE</p>
              <p>Brian C. Bucca, OD, FAAO</p>
              <p>Marcella Chavez, RN, AS</p>
              <p>Sherron Cook</p>
              <p>Jeff Curtis, MD</p>
              <p>Tara Dacawyma</p>
              <p>Matthew S. Doughty, MD</p>
              <p>Roberta Duncan, RD</p>
              <p>Charlotte Dodge</p>
              <p>Cyndy Edgerton, RD</p>
              <p>Jacqueline M. Ghahate</p>
              <p>Justin Glass, MD</p>
              <p>Martia Glass, MD</p>
              <p>Dorothy Gohdes, MD</p>
              <p>Wendy Grant, MD</p>
              <p>Robert L. Hanson, MD, MPH</p>
              <p>Ellie Horse</p>
              <p>Louise E. Ingraham, MS, RD, LN</p>
              <p>Merry Jackson</p>
              <p>Priscilla Jay</p>
              <p>Roylen S. Kaskalla</p>
              <p>David Kessler, MD</p>
              <p>Kathleen M. Kobus, RNC-ANP</p>
              <p>Jonathan Krakoff, MD</p>
              <p>Jason Kurland, MD</p>
              <p>Catherine Manus, LPN</p>
              <p>Cherie McCabe</p>
              <p>Sara Michaels, MD</p>
              <p>Tina Morgan</p>
              <p>Yolanda Nashboo</p>
              <p>Julie A. Nelson, RD</p>
              <p>Steven Poirier, MD</p>
              <p>Evette Polczynski, MD</p>
              <p>Christopher Piromalli, DO</p>
              <p>Mike Reidy, MD</p>
              <p>Jeanine Roumain, MD, MPH</p>
              <p>Debra Rowse, MD</p>
              <p>Robert J. Roy</p>
              <p>Sandra Sangster, RD</p>
              <p>Janet Sewenemewa</p>
              <p>Miranda Smart</p>
              <p>Darryl Tonemah, PhD</p>
              <p>Rachel Williams, FNP</p>
              <p>Charlton Wilson, MD</p>
              <p>Michelle Yazzie</p>
            </sec>
            <sec id="s0129">
              <title>George Washington University Biostatistics Center (DPP Coordinating Center Rockville, MD)</title>
              <p>Raymond Bain, PhD*</p>
              <p>Sarah Fowler, PhD*</p>
              <p>Marinella Temprosa, PhD*</p>
              <p>Michael D. Larsen, PhD*</p>
              <p>Tina Brenneman**</p>
              <p>Sharon L. Edelstein, ScM**</p>
              <p>Solome Abebe, MS</p>
              <p>Julie Bamdad, MS</p>
              <p>Melanie Barkalow</p>
              <p>Joel Bethepu, MPH</p>
              <p>Tsedenia Bezabeh, MS</p>
              <p>Nicole Butler, MPH</p>
              <p>Jackie Callaghan</p>
              <p>Caitlin E. Carter, MPH</p>
              <p>Costas Christophi, PhD</p>
              <p>Gregory M. Dwyer, MPH</p>
              <p>Mary Foulkes, PhD</p>
              <p>Yuping Gao</p>
              <p>Robert Gooding</p>
              <p>Adrienne Gottlieb</p>
              <p>Kristina L. Grimes</p>
              <p>Nisha Grover-Fairchild, MPH</p>
              <p>Lori Haffner, MS</p>
              <p>Heather Hoffman, PhD</p>
              <p>Kathleen Jablonski, PhD</p>
              <p>Steve Jones</p>
              <p>Tara L. Jones</p>
              <p>Richard Katz, MD</p>
              <p>Preethy Kolinjivadi, MS</p>
              <p>John M. Lachin, ScD</p>
              <p>Yong Ma, PhD</p>
              <p>Pamela Mucik</p>
              <p>Robert Orlosky</p>
              <p>Qing Pan, PhD</p>
              <p>Susan Reamer</p>
              <p>James Rochon, PhD</p>
              <p>Alla Sapozhnikova</p>
              <p>Hanna Sherif, MS</p>
              <p>Charlotte Stimpson</p>
              <p>Ashley Hogan Tjaden, MPH</p>
              <p>Fredricka Walker-Murray</p>
            </sec>
            <sec id="s0130">
              <title>Lifestyle Resource Core</title>
              <p>Elizabeth M. Venditti, PhD*</p>
              <p>Andrea M. Kriska, PhD</p>
              <p>Linda Semler, MS, RD, LDN</p>
              <p>Valerie Weinzierl, MPH</p>
            </sec>
            <sec id="s0131">
              <title>Central Biochemistry Laboratory (Seattle, WA)</title>
              <p>Santica Marcovina, PhD, ScD*</p>
              <p>Jessica Harting**</p>
              <p>F. Alan Aldrich**</p>
              <p>John Albers, PhD</p>
              <p>Greg Strylewicz, PhD</p>
            </sec>
            <sec id="s0132">
              <title>National Institutes of Health/National Institute of Diabetes and Digestive and Kidney (NIDDK) (Bethesda, MD)</title>
              <p>R. Eastman, MD</p>
              <p>Judith Fradkin, MD</p>
              <p>Sanford Garfield, PhD</p>
              <p>Christine Lee, MD, MS</p>
            </sec>
            <sec id="s0133">
              <title>Centers for Disease Control &amp; Prevention (Atlanta, GA)</title>
              <p>Edward Gregg, PhD</p>
              <p>Ping Zhang, PhD</p>
            </sec>
            <sec id="s0134">
              <title>Carotid Ultrasound</title>
              <p>Dan O’Leary, MD*</p>
              <p>Gregory Evans</p>
            </sec>
            <sec id="s0135">
              <title>Coronary Artery Calcification Reading Center</title>
              <p>Matthew Budoff, MD</p>
              <p>Chris Dailing</p>
            </sec>
            <sec id="s0136">
              <title>CT Scan Reading Center</title>
              <p>Elizabeth Stamm, MD*</p>
            </sec>
            <sec id="s0137">
              <title>Dual Energy X-ray Absorptiometry Reading Center (San Francisco, CA)</title>
              <p>Ann Schwartz, PhD</p>
              <p>Caroline Navy</p>
              <p>Lisa Palermo, MS</p>
            </sec>
            <sec id="s0138">
              <title>Epidemiological Cardiology Research Center—Epicare (Winston-Salem, NC)</title>
              <p>Pentti Rautaharju, MD, PhD*</p>
              <p>Ronald J. Prineas, MD, PhD**</p>
              <p>Teresa Alexander</p>
              <p>Charles Campbell, MS</p>
              <p>Sharon Hall</p>
              <p>Yabing Li, MD</p>
              <p>Margaret Mills</p>
              <p>Nancy Pemberton, MS</p>
              <p>Farida Rautaharju, PhD</p>
              <p>Zhuming Zhang, MD</p>
              <p>Elsayed Z. Soliman, MD*</p>
              <p>Julie Hu, MSc</p>
              <p>Susan Hensley, BS</p>
              <p>Lisa Keasler</p>
              <p>Tonya Taylor</p>
            </sec>
            <sec id="s0139">
              <title>Fundus Photo Reading Center (Madison, WI)</title>
              <p>Ronald Danis, MD*</p>
              <p>Matthew Davis, MD*</p>
              <p>Larry Hubbard*</p>
              <p>Ryan Endres**</p>
              <p>Deborah Elsas**</p>
              <p>Samantha Johnson**</p>
              <p>Vonnie Gama</p>
              <p>Anne Goulding</p>
            </sec>
            <sec id="s0140">
              <title>Neurocognitive Assessment Group</title>
              <p>Jose A. Luchsinger, MD, MPH</p>
              <p>Jennifer Manly, PhD</p>
            </sec>
            <sec id="s0141">
              <title>Nutrition Coding Center (Columbia, SC)</title>
              <p>Elizabeth Mayer-Davis, PhD*</p>
              <p>Robert R. Moran, PhD**</p>
            </sec>
            <sec id="s0142">
              <title>Quality of Well-Being Center (La Jolla, CA)</title>
              <p>Ted Ganiats, MD*</p>
              <p>Kristin David, MHP*</p>
              <p>Andrew J. Sarkin, PhD*</p>
              <p>Erik Groessl, PhD</p>
              <p>Naomi Katzir</p>
            </sec>
            <sec id="s0143">
              <title>University of Michigan (Ann Arbor, MI)</title>
              <p>William H. Herman, MD, MPH</p>
              <p>Michael Brändle, MD, MS</p>
              <p>Morton B. Brown, PhD</p>
            </sec>
            <sec id="s0144">
              <title>+Genetics Working Group</title>
              <p>Jose C. Florez, MD, PhD<sup>1, 2</sup></p>
              <p>David Altshuler, MD, PhD<sup>1, 2</sup></p>
              <p>Liana K. Billings, MD<sup>1</sup></p>
              <p>Ling Chen, MS<sup>1</sup></p>
              <p>Maegan Harden, BS<sup>2</sup></p>
              <p>Robert L. Hanson, MD, MPH<sup>3</sup></p>
              <p>William C. Knowler, MD, DrPH<sup>3</sup></p>
              <p>Toni I. Pollin, PhD<sup>4</sup></p>
              <p>Alan R. Shuldiner, MD<sup>4</sup></p>
              <p>Kathleen Jablonski, PhD<sup>5</sup></p>
              <p>Paul W. Franks, PhD, MPhil, MS<sup>6, 7, 8</sup></p>
              <p>Marie-France Hivert, MD<sup>9</sup></p>
              <p>1=Massachusetts General Hospital</p>
              <p>2=Broad Institute</p>
              <p>3=NIDDK</p>
              <p>4=University of Maryland</p>
              <p>5=Coordinating Center</p>
              <p>6=Lund University, Sweden</p>
              <p>7=Umeå University, Sweden</p>
              <p>8=Harvard School of Public Health</p>
              <p>9=Université de Sherbrooke</p>
              <p><bold><italic toggle="yes">Financial Support:</italic></bold> During the DPP and DPPOS, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data (U01 DK048489). The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, and the Department of Veterans Affairs supported data collection at many of the clinical centers. Funding was also provided by the National Institute of Child Health and Human Development, the National Institute on Aging, the National Eye Institute, the National Heart Lung and Blood Institute, the National Cancer Institute, the Office of Research on Women’s Health, the National Institute on Minority Health and Health Disparities, the Centers for Disease Control and Prevention, and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided additional funding and material support during the DPP, Lipha (Merck-Sante) provided medication, and LifeScan Inc. donated materials during the DPP and DPPOS. This research was also supported, in part, by the intramural research program of the NIDDK. LifeScan Inc., Health O Meter, Hoechst Marion Roussel, Inc., Merck-Medco Managed Care, Inc., Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and Quaker Oats Co. donated materials, equipment, or medicines for concomitant conditions. McKesson BioServices Corp., Matthews Media Group, Inc., and the Henry M. Jackson Foundation provided support services under subcontract with the Coordinating Center.</p>
              <p><bold><italic toggle="yes">Clinical Trial Information:</italic></bold> ClinicalTrials.gov registration no. NCT00004992.</p>
            </sec>
            <sec id="s0145">
              <title>Additional Information</title>
              <p><bold><italic toggle="yes">Disclosures:</italic></bold> The sponsor of this study was represented on the Steering Committee and played a part in study design, how the study was done, and publication. The funding agency was not represented on the writing group, although all members of the Steering Committee had input into the report’s contents. All authors in the writing group had access to all data. The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies. A complete list of Centers, investigators, and staff can be found in the Appendix. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Kieren Mather received a research grant from Novo IIT and has also medication or supply donations with aggregate value &gt;$10 000 for other research studies from Novo, Sanofi, Merck, and Abbott. The other authors declare no conflict of interest.</p>
            </sec>
            <sec sec-type="data-availability" id="s0146">
              <title>Data Availability</title>
              <p>In accordance with the NIH Public Access Policy, we continue to provide all manuscripts to PubMed Central including this manuscript. DPP/DPPOS has provided the protocols and lifestyle and medication intervention manuals to the public through its public website (<ext-link xlink:href="https://www.dppos.org" ext-link-type="uri">https://www.dppos.org</ext-link>). The DPPOS abides by the NIDDK data sharing policy and implementation guidance as required by the NIH/NIDDK (<ext-link xlink:href="https://www.niddkrepository.org/studies/dppos/" ext-link-type="uri">https://www.niddkrepository.org/studies/dppos/</ext-link>).</p>
            </sec>
            <ref-list id="r1">
              <title>References</title>
              <ref id="CIT0001">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williams</surname><given-names>KH</given-names></string-name>, <string-name><surname>Shackel</surname><given-names>NA</given-names></string-name>, <string-name><surname>Gorrell</surname><given-names>MD</given-names></string-name>, <string-name><surname>McLennan</surname><given-names>SV</given-names></string-name>, <string-name><surname>Twigg</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo</article-title>. <source>Endocr Rev.</source><year>2013</year>;<volume>34</volume>(<issue>1</issue>):<fpage>84</fpage>-<lpage>129</lpage>.<pub-id pub-id-type="pmid">23238855</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0002">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birkenfeld</surname><given-names>AL</given-names></string-name>, <string-name><surname>Shulman</surname><given-names>GI</given-names></string-name></person-group>. <article-title>Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes</article-title>. <source>Hepatology.</source><year>2014</year>;<volume>59</volume>(<issue>2</issue>):<fpage>713</fpage>-<lpage>723</lpage>.<pub-id pub-id-type="pmid">23929732</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0003">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bae</surname><given-names>JC</given-names></string-name>, <string-name><surname>Cho</surname><given-names>YK</given-names></string-name>, <string-name><surname>Lee</surname><given-names>WY</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects</article-title>. <source>Am J Gastroenterol.</source><year>2010</year>;<volume>105</volume>(<issue>11</issue>):<fpage>2389</fpage>-<lpage>2395</lpage>.<pub-id pub-id-type="pmid">20628364</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0004">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lallukka</surname><given-names>S</given-names></string-name>, <string-name><surname>Yki-Järvinen</surname><given-names>H</given-names></string-name></person-group>. <article-title>Non-alcoholic fatty liver disease and risk of type 2 diabetes</article-title>. <source>Best Pract Res Clin Endocrinol Metab.</source><year>2016</year>;<volume>30</volume>(<issue>3</issue>):<fpage>385</fpage>-<lpage>395</lpage>.<pub-id pub-id-type="pmid">27432073</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0005">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Knowler</surname><given-names>WC</given-names></string-name>, <string-name><surname>Barrett-Connor</surname><given-names>E</given-names></string-name>, <string-name><surname>Fowler</surname><given-names>SE</given-names></string-name>, <etal>et al.</etal></person-group>; <person-group><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title>. <source>N Engl J Med.</source><year>2002</year>;<volume>346</volume>(<issue>6</issue>):<fpage>393</fpage>-<lpage>403</lpage>.<pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0006">
                <label>6.</label>
                <mixed-citation publication-type="journal"><collab>Diabetes Prevention Program Research Group</collab>, <person-group person-group-type="author"><string-name><surname>Knowler</surname><given-names>WC</given-names></string-name>, <string-name><surname>Fowler</surname><given-names>SE</given-names></string-name>, <string-name><surname>Hamman</surname><given-names>RF</given-names></string-name></person-group>; <etal>et al.</etal><article-title>10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study</article-title>. <source>Lancet</source>. <year>2009</year>; <volume>374</volume>(<issue>9702</issue>):<fpage>1677</fpage>−
<lpage>1686</lpage>.<pub-id pub-id-type="pmid">19878986</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0007">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldberg</surname><given-names>RB</given-names></string-name>, <string-name><surname>Aroda</surname><given-names>VR</given-names></string-name>, <string-name><surname>Bluemke</surname><given-names>DA</given-names></string-name>, <etal>et al.</etal></person-group>; <person-group><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium</article-title>. <source>Circulation.</source><year>2017</year>;<volume>136</volume>(<issue>1</issue>):<fpage>52</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="pmid">28476766</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0008">
                <label>8.</label>
                <mixed-citation publication-type="journal"><collab>Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</collab>.<article-title> Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997)</article-title>. <source>Diabetes Care.</source><year>1997</year>; <volume>20</volume>(<issue>7</issue>):<fpage>1183</fpage>-<lpage>1197</lpage>.<pub-id pub-id-type="pmid">9203460</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0009">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mather</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Funahashi</surname><given-names>T</given-names></string-name>, <string-name><surname>Matsuzawa</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>; <person-group><collab>Diabetes Prevention Program</collab></person-group>. <article-title>Change in adiponectin, and progression to diabetes in the Diabetes Prevention Program</article-title>. <source>Diabetes</source><year>. 2008</year>; <volume>57</volume>(<issue>4</issue>):<fpage>980</fpage>-<lpage>986</lpage>.<pub-id pub-id-type="pmid">18192541</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0010">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldberg</surname><given-names>RB</given-names></string-name>, <string-name><surname>Temprosa</surname><given-names>MG</given-names></string-name>, <string-name><surname>Mather</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Orchard</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Kitabchi</surname><given-names>AE</given-names></string-name>, <string-name><surname>Watson</surname><given-names>KE</given-names></string-name></person-group>; <person-group><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes</article-title>. <source>Diabetes Care.</source><year>2014</year>;<volume>37</volume>(<issue>8</issue>):<fpage>2253</fpage>-<lpage>2260</lpage>.<pub-id pub-id-type="pmid">24824548</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0011">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Sullivan</surname><given-names>JF</given-names></string-name>, <string-name><surname>Morningstar</surname><given-names>JE</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes</article-title>. <source>J Clin Invest.</source><year>2017</year>;<volume>127</volume>(<issue>12</issue>):<fpage>4394</fpage>-<lpage>4402</lpage>.<pub-id pub-id-type="pmid">29083323</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0012">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kodama</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ng</surname><given-names>CS</given-names></string-name>, <string-name><surname>Wu</surname><given-names>TT</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Comparison of CT methods for determining the fat content of the liver</article-title>. <source>AJR Am J Roentgenol.</source><year>2007</year>;<volume>188</volume>(<issue>5</issue>):<fpage>1307</fpage>-<lpage>1312</lpage>.<pub-id pub-id-type="pmid">17449775</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0013">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pickhardt</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Park</surname><given-names>SH</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>L</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SG</given-names></string-name>, <string-name><surname>Bae</surname><given-names>KT</given-names></string-name>, <string-name><surname>Yu</surname><given-names>ES</given-names></string-name></person-group>. <article-title>Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis</article-title>. <source>Eur Radiol.</source><year>2012</year>;<volume>22</volume>(<issue>5</issue>):<fpage>1075</fpage>-<lpage>1082</lpage>.<pub-id pub-id-type="pmid">22138733</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0014">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyce</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Pickhardt</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Kim</surname><given-names>DH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT</article-title>. <source>AJR Am J Roentgenol.</source><year>2010</year>;<volume>194</volume>(<issue>3</issue>):<fpage>623</fpage>-<lpage>628</lpage>.<pub-id pub-id-type="pmid">20173137</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0015">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeb</surname><given-names>I</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Nasir</surname><given-names>K</given-names></string-name>, <string-name><surname>Katz</surname><given-names>R</given-names></string-name>, <string-name><surname>Larijani</surname><given-names>VN</given-names></string-name>, <string-name><surname>Budoff</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis</article-title>. <source>Acad Radiol</source>. <year>2012</year>; <volume>197</volume>(<issue>7</issue>):<fpage>811</fpage>-<lpage>818</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0016">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Browning</surname><given-names>JD</given-names></string-name>, <string-name><surname>Szczepaniak</surname><given-names>LS</given-names></string-name>, <string-name><surname>Dobbins</surname><given-names>R</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity</article-title>. <source>Hepatology.</source><year>2004</year>;<volume>40</volume>(<issue>6</issue>):<fpage>1387</fpage>-<lpage>1395</lpage>.<pub-id pub-id-type="pmid">15565570</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0017">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romeo</surname><given-names>S</given-names></string-name>, <string-name><surname>Kozlitina</surname><given-names>J</given-names></string-name>, <string-name><surname>Xing</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease</article-title>. <source>Nat Genet.</source><year>2008</year>;<volume>40</volume>(<issue>12</issue>):<fpage>1461</fpage>-<lpage>1465</lpage>.<pub-id pub-id-type="pmid">18820647</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0018">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tota-Maharaj</surname><given-names>R</given-names></string-name>, <string-name><surname>Blaha</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Zeb</surname><given-names>I</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis</article-title>. <source>Mayo Clin Proc</source>. <year>2014</year>; <volume>89</volume>(<issue>4</issue>):<fpage>493</fpage>-<lpage>503</lpage>.<pub-id pub-id-type="pmid">24613289</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0019">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakajima</surname><given-names>T</given-names></string-name>, <string-name><surname>Nakashima</surname><given-names>T</given-names></string-name>, <string-name><surname>Yamaoka</surname><given-names>J</given-names></string-name>, <string-name><surname>Shibuya</surname><given-names>A</given-names></string-name>, <string-name><surname>Itoh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yoshikawa</surname><given-names>T</given-names></string-name></person-group>. <article-title>Age is a negative, and visceral fat accumulation is a positive, contributor to hepatic steatosis, regardless of the fibrosis progression in non-alcoholic fatty liver disease</article-title>. <source>J Gastroenterol Hepatol Res</source>. <year>2012</year>;<volume>1</volume>(11):
<fpage>315</fpage>-<lpage>319</lpage>.</mixed-citation>
              </ref>
              <ref id="CIT0020">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thomas</surname><given-names>EL</given-names></string-name>, <string-name><surname>Brynes</surname><given-names>AE</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease</article-title>. <source>World J Gastroenterol.</source><year>2006</year>;<volume>12</volume>(<issue>36</issue>):<fpage>5813</fpage>-<lpage>5819</lpage>.<pub-id pub-id-type="pmid">17007047</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0021">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tiikkainen</surname><given-names>M</given-names></string-name>, <string-name><surname>Häkkinen</surname><given-names>AM</given-names></string-name>, <string-name><surname>Korsheninnikova</surname><given-names>E</given-names></string-name>, <string-name><surname>Nyman</surname><given-names>T</given-names></string-name>, <string-name><surname>Mäkimattila</surname><given-names>S</given-names></string-name>, <string-name><surname>Yki-Järvinen</surname><given-names>H</given-names></string-name></person-group>. <article-title>Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes</article-title>. <source>Diabetes.</source><year>2004</year>;<volume>53</volume>(<issue>8</issue>):<fpage>2169</fpage>-<lpage>2176</lpage>.<pub-id pub-id-type="pmid">15277403</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0022">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>VanWagner</surname><given-names>LB</given-names></string-name>, <string-name><surname>Ning</surname><given-names>H</given-names></string-name>, <string-name><surname>Allen</surname><given-names>NB</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease</article-title>. <source>Liver Int.</source><year>2018</year>;<volume>38</volume>(<issue>11</issue>):<fpage>2069</fpage>-<lpage>2081</lpage>.<pub-id pub-id-type="pmid">29608255</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0023">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>VanWagner</surname><given-names>LB</given-names></string-name>, <string-name><surname>Ning</surname><given-names>H</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CE</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study</article-title>. <source>Atherosclerosis.</source><year>2014</year>;<volume>235</volume>(<issue>2</issue>):<fpage>599</fpage>-<lpage>605</lpage>.<pub-id pub-id-type="pmid">24956534</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0024">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gatselis</surname><given-names>NK</given-names></string-name>, <string-name><surname>Ntaios</surname><given-names>G</given-names></string-name>, <string-name><surname>Makaritsis</surname><given-names>K</given-names></string-name>, <string-name><surname>Dalekos</surname><given-names>GN</given-names></string-name></person-group>. <article-title>Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease</article-title>. <source>Clin Exp Med.</source><year>2014</year>;<volume>14</volume>(<issue>2</issue>):<fpage>121</fpage>-<lpage>131</lpage>.<pub-id pub-id-type="pmid">23292294</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0025">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>ML</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>CM</given-names></string-name>, <string-name><surname>Tseng</surname><given-names>JH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders</article-title>. <source>J Gastroenterol Hepatol.</source><year>2015</year>;<volume>30</volume>(<issue>2</issue>):<fpage>329</fpage>-<lpage>336</lpage>.<pub-id pub-id-type="pmid">25091195</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0026">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>K</given-names></string-name>, <string-name><surname>Ryu</surname><given-names>S</given-names></string-name>, <string-name><surname>Chang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kim</surname><given-names>HR</given-names></string-name></person-group>. <article-title>High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men</article-title>. <source>Plos One.</source><year>2017</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e0172666</fpage>.<pub-id pub-id-type="pmid">28234943</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0027">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Després</surname><given-names>JP</given-names></string-name>, <string-name><surname>Lemieux</surname><given-names>I</given-names></string-name>, <string-name><surname>Bergeron</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk</article-title>. <source>Arterioscler Thromb Vasc Biol.</source><year>2008</year>;<volume>28</volume>(<issue>6</issue>):<fpage>1039</fpage>-<lpage>1049</lpage>.<pub-id pub-id-type="pmid">18356555</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0028">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adiels</surname><given-names>M</given-names></string-name>, <string-name><surname>Taskinen</surname><given-names>MR</given-names></string-name>, <string-name><surname>Packard</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Overproduction of large VLDL particles is driven by increased liver fat content in man</article-title>. <source>Diabetologia.</source><year>2006</year>;<volume>49</volume>(<issue>4</issue>):<fpage>755</fpage>-<lpage>765</lpage>.<pub-id pub-id-type="pmid">16463046</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0029">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smagris</surname><given-names>E</given-names></string-name>, <string-name><surname>Gilyard</surname><given-names>S</given-names></string-name>, <string-name><surname>BasuRay</surname><given-names>S</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>JC</given-names></string-name>, <string-name><surname>Hobbs</surname><given-names>HH</given-names></string-name></person-group>. <article-title>Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins</article-title>. <source>J Biol Chem.</source><year>2016</year>;<volume>291</volume>(<issue>20</issue>):<fpage>10659</fpage>-<lpage>10676</lpage>.<pub-id pub-id-type="pmid">27013658</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0030">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Musso</surname><given-names>G</given-names></string-name>, <string-name><surname>Gambino</surname><given-names>R</given-names></string-name>, <string-name><surname>Cassader</surname><given-names>M</given-names></string-name>, <string-name><surname>Pagano</surname><given-names>G</given-names></string-name></person-group>. <article-title>Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity</article-title>. <source>Ann Med.</source><year>2011</year>;<volume>43</volume>(<issue>8</issue>):<fpage>617</fpage>-<lpage>649</lpage>.<pub-id pub-id-type="pmid">21039302</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0031">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leite</surname><given-names>NC</given-names></string-name>, <string-name><surname>Villela-Nogueira</surname><given-names>CA</given-names></string-name>, <string-name><surname>Pannain</surname><given-names>VL</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors</article-title>. <source>Liver Int.</source><year>2011</year>;<volume>31</volume>(<issue>5</issue>):<fpage>700</fpage>-<lpage>706</lpage>.<pub-id pub-id-type="pmid">21457442</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0032">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yilmaz</surname><given-names>Y</given-names></string-name>, <string-name><surname>Senates</surname><given-names>E</given-names></string-name>, <string-name><surname>Yesil</surname><given-names>A</given-names></string-name>, <string-name><surname>Ergelen</surname><given-names>R</given-names></string-name>, <string-name><surname>Colak</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease</article-title>. <source>J Diabetes Complications.</source><year>2014</year>;<volume>28</volume>(<issue>3</issue>):<fpage>328</fpage>-<lpage>331</lpage>.<pub-id pub-id-type="pmid">24602757</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0033">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Targher</surname><given-names>G</given-names></string-name>, <string-name><surname>Bertolini</surname><given-names>L</given-names></string-name>, <string-name><surname>Rodella</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients</article-title>. <source>Diabetologia.</source><year>2008</year>;<volume>51</volume>(<issue>3</issue>):<fpage>444</fpage>-<lpage>450</lpage>.<pub-id pub-id-type="pmid">18058083</pub-id></mixed-citation>
              </ref>
              <ref id="CIT0034">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Targher</surname><given-names>G</given-names></string-name>, <string-name><surname>Day</surname><given-names>CP</given-names></string-name>, <string-name><surname>Bonora</surname><given-names>E</given-names></string-name></person-group>. <article-title>Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease</article-title>. <source>N Engl J Med.</source><year>2010</year>;<volume>363</volume>(<issue>14</issue>):<fpage>1341</fpage>-<lpage>1350</lpage>.<pub-id pub-id-type="pmid">20879883</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
